JP2013528660A - D2アンタゴニスト、その合成方法および使用方法 - Google Patents
D2アンタゴニスト、その合成方法および使用方法 Download PDFInfo
- Publication number
- JP2013528660A JP2013528660A JP2013515569A JP2013515569A JP2013528660A JP 2013528660 A JP2013528660 A JP 2013528660A JP 2013515569 A JP2013515569 A JP 2013515569A JP 2013515569 A JP2013515569 A JP 2013515569A JP 2013528660 A JP2013528660 A JP 2013528660A
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- triazaspiro
- methyl
- phenyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000005557 antagonist Substances 0.000 title claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 358
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- -1 2-oxo-2,3-dihydro-1H-benzo [d] imidazol-1-yl Chemical group 0.000 claims description 284
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 220
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 162
- 239000000203 mixture Substances 0.000 claims description 140
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 91
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 22
- 238000010992 reflux Methods 0.000 claims description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 206010047700 Vomiting Diseases 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 230000002496 gastric effect Effects 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 201000006549 dyspepsia Diseases 0.000 claims description 7
- 230000008673 vomiting Effects 0.000 claims description 7
- 206010000060 Abdominal distension Diseases 0.000 claims description 6
- 230000005176 gastrointestinal motility Effects 0.000 claims description 6
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 4
- 230000000291 postprandial effect Effects 0.000 claims description 4
- 210000005070 sphincter Anatomy 0.000 claims description 4
- HIRDKMWBLSFJAO-NDEPHWFRSA-N (2s)-2-[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C1CN(CCCC(=O)C=2C=CC=CC=2)CCC21C(=O)N([C@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 HIRDKMWBLSFJAO-NDEPHWFRSA-N 0.000 claims description 3
- CIQZXMLBBUXWFP-MHZLTWQESA-N (2s)-2-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C1CN(CCCN2C(NC3=CC=CC=C32)=O)CCC21C(=O)N([C@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 CIQZXMLBBUXWFP-MHZLTWQESA-N 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 206010059186 Early satiety Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 229960002428 fentanyl Drugs 0.000 claims description 3
- 208000024798 heartburn Diseases 0.000 claims description 3
- 208000008384 ileus Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 239000000014 opioid analgesic Substances 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229960001391 alfentanil Drugs 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 claims description 2
- 229950004689 carfentanil Drugs 0.000 claims description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical group C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 2
- 229960005132 cisapride Drugs 0.000 claims description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 208000020694 gallbladder disease Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 208000001288 gastroparesis Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims description 2
- 229950010274 lofentanil Drugs 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 229960004085 mosapride Drugs 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 229960003394 remifentanil Drugs 0.000 claims description 2
- 230000033764 rhythmic process Effects 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004739 sufentanil Drugs 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 2
- 229960002876 tegaserod Drugs 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- 230000009278 visceral effect Effects 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 18
- 229960003638 dopamine Drugs 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 230000001404 mediated effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 602
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 510
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 492
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 242
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 226
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 190
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 189
- 239000011541 reaction mixture Substances 0.000 description 184
- 239000000243 solution Substances 0.000 description 180
- 238000003756 stirring Methods 0.000 description 156
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 129
- 229910000027 potassium carbonate Inorganic materials 0.000 description 121
- 235000011181 potassium carbonates Nutrition 0.000 description 121
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 120
- 239000012267 brine Substances 0.000 description 118
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 118
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 105
- 238000002360 preparation method Methods 0.000 description 104
- 238000006243 chemical reaction Methods 0.000 description 84
- 238000003818 flash chromatography Methods 0.000 description 83
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 82
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 81
- 239000000047 product Substances 0.000 description 76
- 239000012074 organic phase Substances 0.000 description 64
- 239000012044 organic layer Substances 0.000 description 62
- 239000007787 solid Substances 0.000 description 61
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 56
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 56
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 52
- 239000003921 oil Substances 0.000 description 49
- 235000019198 oils Nutrition 0.000 description 49
- 238000012746 preparative thin layer chromatography Methods 0.000 description 46
- 235000009518 sodium iodide Nutrition 0.000 description 43
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 36
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 34
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 30
- 238000001816 cooling Methods 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- FGNNKGBZNGGQNH-UHFFFAOYSA-N tert-butyl 3-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCNCC3)N(C=3C=CC=CC=3)C2)=O)=C1 FGNNKGBZNGGQNH-UHFFFAOYSA-N 0.000 description 24
- MJEDMNFDMFAELH-UHFFFAOYSA-N 3-(3-iodopropyl)-1h-benzimidazol-2-one Chemical compound C1=CC=C2NC(=O)N(CCCI)C2=C1 MJEDMNFDMFAELH-UHFFFAOYSA-N 0.000 description 23
- 238000004809 thin layer chromatography Methods 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 150000003840 hydrochlorides Chemical class 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- 239000000843 powder Substances 0.000 description 21
- 159000000021 acetate salts Chemical class 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 239000006071 cream Substances 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- JRKPNHLSQGAUDY-UHFFFAOYSA-N 1,3,8-triazaspiro[4.5]decan-4-one Chemical compound O=C1NCNC11CCNCC1 JRKPNHLSQGAUDY-UHFFFAOYSA-N 0.000 description 17
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 17
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 17
- 235000019253 formic acid Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 10
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 10
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 10
- BRVSNRACQLWLFE-UHFFFAOYSA-N 1,3,8-triazaspiro[4.5]dec-1-en-4-one Chemical compound O=C1NC=NC11CCNCC1 BRVSNRACQLWLFE-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- RCBQSHWYAZPHPN-UHFFFAOYSA-N benzyl 4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CC2(C(NCN2C=2C=CC=CC=2)=O)CCN1C(=O)OCC1=CC=CC=C1 RCBQSHWYAZPHPN-UHFFFAOYSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000002287 radioligand Substances 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- QNLHZVMOBJUSKG-UHFFFAOYSA-N tert-butyl 3-[[1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCNCC3)N(C=3C=CC(F)=CC=3)C2)=O)=C1 QNLHZVMOBJUSKG-UHFFFAOYSA-N 0.000 description 8
- 230000003474 anti-emetic effect Effects 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- WLSXAPNATDBIRA-UHFFFAOYSA-N methyl 3-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCNCC3)N(C=3C=CC=CC=3)C2)=O)=C1 WLSXAPNATDBIRA-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FECCCPYXQKSZQC-UHFFFAOYSA-N tert-butyl 2-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 FECCCPYXQKSZQC-UHFFFAOYSA-N 0.000 description 7
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 6
- AOTDNOWGWHWLLP-UHFFFAOYSA-N 1-(3-chloropropyl)-3,3-dimethylindol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)N(CCCCl)C2=C1 AOTDNOWGWHWLLP-UHFFFAOYSA-N 0.000 description 6
- IHCPVVHNBTWTGI-UHFFFAOYSA-N 1-(3-chloropropyl)-3h-indol-2-one Chemical compound C1=CC=C2N(CCCCl)C(=O)CC2=C1 IHCPVVHNBTWTGI-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000002111 antiemetic agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- BNYZRZNNKWZTKG-UHFFFAOYSA-N tert-butyl 4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)NCN2C1=CC=CC=C1 BNYZRZNNKWZTKG-UHFFFAOYSA-N 0.000 description 6
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 5
- LTZHCFIAKSIPDK-UHFFFAOYSA-N 1'-(3-chloropropyl)spiro[cyclopropane-1,3'-indole]-2'-one Chemical compound C12=CC=CC=C2N(CCCCl)C(=O)C21CC2 LTZHCFIAKSIPDK-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 5
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 5
- 229940049953 phenylacetate Drugs 0.000 description 5
- 239000004317 sodium nitrate Substances 0.000 description 5
- 235000010344 sodium nitrate Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HGVVNIOTQHSVCO-UHFFFAOYSA-N tert-butyl 2-[[1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC(F)=CC=2)C1 HGVVNIOTQHSVCO-UHFFFAOYSA-N 0.000 description 5
- FWVVBSNKXPFYMT-UHFFFAOYSA-N tert-butyl 3-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CBr)=C1 FWVVBSNKXPFYMT-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- WNTGDRAKHRGTGG-UHFFFAOYSA-N 1-(3-chloropropyl)-3-cyclopropylbenzimidazol-2-one Chemical compound O=C1N(CCCCl)C2=CC=CC=C2N1C1CC1 WNTGDRAKHRGTGG-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- GHEFQKHLHFXSBR-UHFFFAOYSA-N 4-chloro-1-phenylbutan-1-one Chemical compound ClCCCC(=O)C1=CC=CC=C1 GHEFQKHLHFXSBR-UHFFFAOYSA-N 0.000 description 4
- QCNSLBGKXIACGC-UHFFFAOYSA-N 4-iodo-1-phenylbutan-1-one Chemical compound ICCCC(=O)C1=CC=CC=C1 QCNSLBGKXIACGC-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 229940125683 antiemetic agent Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- NHFBYYMNJUMVOT-QMMMGPOBSA-N methyl (2s)-2-bromo-2-phenylacetate Chemical compound COC(=O)[C@@H](Br)C1=CC=CC=C1 NHFBYYMNJUMVOT-QMMMGPOBSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DHGAJRQKHOZASX-UHFFFAOYSA-N tert-butyl 3-[(1-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCNCC3)N(C3CCCCC3)C2)=O)=C1 DHGAJRQKHOZASX-UHFFFAOYSA-N 0.000 description 4
- FBSAPBMYEZDXEM-JOCHJYFZSA-N tert-butyl 3-[(1r)-2-methoxy-2-oxo-1-phenylethyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N([C@@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 FBSAPBMYEZDXEM-JOCHJYFZSA-N 0.000 description 4
- BIWQQZQYPQMZPB-UHFFFAOYSA-N tert-butyl 3-[(3-methoxycarbonylphenyl)methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CC3)C(=O)OC(C)(C)C)N(C=3C=CC=CC=3)C2)=O)=C1 BIWQQZQYPQMZPB-UHFFFAOYSA-N 0.000 description 4
- LFPHGPJWDVNGSO-UHFFFAOYSA-N tert-butyl 4-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 LFPHGPJWDVNGSO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 3
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 3
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 3
- QXHSJOPLBLUXOO-UHFFFAOYSA-N 1-(3-chloropropyl)-3-fluoro-3-methylindol-2-one Chemical compound C1=CC=C2C(C)(F)C(=O)N(CCCCl)C2=C1 QXHSJOPLBLUXOO-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 3
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 3
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 3
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 3
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 3
- JYDGSKVDLROELR-UHFFFAOYSA-N 3-(3-iodopropyl)-1,3-benzothiazol-2-one Chemical compound C1=CC=C2SC(=O)N(CCCI)C2=C1 JYDGSKVDLROELR-UHFFFAOYSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 3
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 3
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 3
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 3
- LQYRHTXYFHGLIN-UHFFFAOYSA-N CC1(C2=CC=CC=C2N(C1=O)CCCN3CCC4(CC3)C(=O)NCN4C5=CC=CC=C5)C Chemical compound CC1(C2=CC=CC=C2N(C1=O)CCCN3CCC4(CC3)C(=O)NCN4C5=CC=CC=C5)C LQYRHTXYFHGLIN-UHFFFAOYSA-N 0.000 description 3
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 101150049660 DRD2 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 3
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- JQGSDDASMJYREU-UHFFFAOYSA-N benzyl 3-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound C=1C=CC(CN2C(C3(CCNCC3)N(C=3C=CC=CC=3)C2)=O)=CC=1C(=O)OCC1=CC=CC=C1 JQGSDDASMJYREU-UHFFFAOYSA-N 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 3
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 3
- 229960001253 domperidone Drugs 0.000 description 3
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
- 150000004675 formic acid derivatives Chemical class 0.000 description 3
- 230000030135 gastric motility Effects 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- ONCIDLKSYXFZDG-MUUNZHRXSA-N methyl (2r)-2-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetate Chemical compound C1CN(CCCN2C(NC3=CC=CC=C32)=O)CCC21C(=O)N([C@@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 ONCIDLKSYXFZDG-MUUNZHRXSA-N 0.000 description 3
- ONCIDLKSYXFZDG-NDEPHWFRSA-N methyl (2s)-2-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetate Chemical compound C1CN(CCCN2C(NC3=CC=CC=C32)=O)CCC21C(=O)N([C@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 ONCIDLKSYXFZDG-NDEPHWFRSA-N 0.000 description 3
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 3
- ZTXUMTOZZPWBQC-UHFFFAOYSA-N methyl 2-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)N(C=2C=CC=CC=2)C1 ZTXUMTOZZPWBQC-UHFFFAOYSA-N 0.000 description 3
- CCGNNZIRPDXEAA-UHFFFAOYSA-N methyl 3-[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]benzoate Chemical compound COC(=O)C1=CC=CC(N2C(C3(CCN(CCCC(=O)C=4C=CC=CC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 CCGNNZIRPDXEAA-UHFFFAOYSA-N 0.000 description 3
- YAQSNMGKMRIVLG-UHFFFAOYSA-N methyl 3-[[8-[3-(3-methyl-2-oxobenzimidazol-1-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(N(C)C5=CC=CC=C54)=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 YAQSNMGKMRIVLG-UHFFFAOYSA-N 0.000 description 3
- DHHCRJYDJWPQFA-UHFFFAOYSA-N methyl 4-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)C2(CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)N(C=2C=CC=CC=2)C1 DHHCRJYDJWPQFA-UHFFFAOYSA-N 0.000 description 3
- QOSHUNNWSOXKIH-UHFFFAOYSA-N methyl 5-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-5-phenylpentanoate Chemical compound C=1C=CC=CC=1C(CCCC(=O)OC)N(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 QOSHUNNWSOXKIH-UHFFFAOYSA-N 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- 102000051367 mu Opioid Receptors Human genes 0.000 description 3
- CURJNMSGPBXOGK-UHFFFAOYSA-N n',n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)N(C(C)C)CCN CURJNMSGPBXOGK-UHFFFAOYSA-N 0.000 description 3
- DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 3
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000013509 system migration Methods 0.000 description 3
- NXEMHHPFETVDLI-JGCGQSQUSA-N tert-butyl (2r)-2-[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetate Chemical compound C1CN(CCCN2C3=CC=CC=C3CC2=O)CCC21C(=O)N([C@@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)CN2C1=CC=CC=C1 NXEMHHPFETVDLI-JGCGQSQUSA-N 0.000 description 3
- FBSAPBMYEZDXEM-QFIPXVFZSA-N tert-butyl 3-[(1s)-2-methoxy-2-oxo-1-phenylethyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N([C@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 FBSAPBMYEZDXEM-QFIPXVFZSA-N 0.000 description 3
- DSMMGMAMVXGNKH-UHFFFAOYSA-N tert-butyl 3-[[1-cyclohexyl-4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(NC5=CC=CC=C54)=O)CC3)N(C3CCCCC3)C2)=O)=C1 DSMMGMAMVXGNKH-UHFFFAOYSA-N 0.000 description 3
- HBHSJXJGKQXLGH-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC(=O)C=4C=CC=CC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 HBHSJXJGKQXLGH-UHFFFAOYSA-N 0.000 description 3
- XAUBDEQDHUMIGO-UHFFFAOYSA-N tert-butyl 3-[[8-[3-[3-(heptanoyloxymethyl)-2-oxobenzimidazol-1-yl]propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound O=C1N(COC(=O)CCCCCC)C2=CC=CC=C2N1CCCN(CC1)CCC1(C1=O)N(C=2C=CC=CC=2)CN1CC1=CC=CC(C(=O)OC(C)(C)C)=C1 XAUBDEQDHUMIGO-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108020001612 μ-opioid receptors Proteins 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- HIRDKMWBLSFJAO-MUUNZHRXSA-N (2r)-2-[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C1CN(CCCC(=O)C=2C=CC=CC=2)CCC21C(=O)N([C@@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 HIRDKMWBLSFJAO-MUUNZHRXSA-N 0.000 description 2
- CIQZXMLBBUXWFP-HHHXNRCGSA-N (2r)-2-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C1CN(CCCN2C(NC3=CC=CC=C32)=O)CCC21C(=O)N([C@@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 CIQZXMLBBUXWFP-HHHXNRCGSA-N 0.000 description 2
- JXKLHMBKHMYCBS-GDLZYMKVSA-N (2r)-2-[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C1CN(CCCN2C3=CC=CC=C3CC2=O)CCC21C(=O)N([C@@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 JXKLHMBKHMYCBS-GDLZYMKVSA-N 0.000 description 2
- VTSANAQSVSCSRD-VWLOTQADSA-N (2s)-2-(4-oxo-1-phenyl-8-phenylmethoxycarbonyl-1,3,8-triazaspiro[4.5]decan-3-yl)-2-phenylacetic acid Chemical compound C1CN(C(=O)OCC=2C=CC=CC=2)CCC21C(=O)N([C@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 VTSANAQSVSCSRD-VWLOTQADSA-N 0.000 description 2
- JXKLHMBKHMYCBS-LJAQVGFWSA-N (2s)-2-[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C1CN(CCCN2C3=CC=CC=C3CC2=O)CCC21C(=O)N([C@H](C(=O)O)C=1C=CC=CC=1)CN2C1=CC=CC=C1 JXKLHMBKHMYCBS-LJAQVGFWSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- HAYPJSAGGJTDBQ-UHFFFAOYSA-N 1-(3-chloropropyl)-3,3-difluoroindol-2-one Chemical compound C1=CC=C2C(F)(F)C(=O)N(CCCCl)C2=C1 HAYPJSAGGJTDBQ-UHFFFAOYSA-N 0.000 description 2
- RWEGYSFMCLCMAJ-UHFFFAOYSA-N 1-(3-chloropropyl)-3-methyl-3h-indol-2-one Chemical compound C1=CC=C2C(C)C(=O)N(CCCCl)C2=C1 RWEGYSFMCLCMAJ-UHFFFAOYSA-N 0.000 description 2
- ADVMORYKIYDWOL-UHFFFAOYSA-N 1-(3-chloropropyl)-3-methylbenzimidazol-2-one Chemical compound C1=CC=C2N(CCCCl)C(=O)N(C)C2=C1 ADVMORYKIYDWOL-UHFFFAOYSA-N 0.000 description 2
- BOLXBKJGTKEMDQ-UHFFFAOYSA-N 1-(3-chloropropyl)benzotriazole Chemical compound C1=CC=C2N(CCCCl)N=NC2=C1 BOLXBKJGTKEMDQ-UHFFFAOYSA-N 0.000 description 2
- PZWAMKNKTMEYNP-UHFFFAOYSA-N 1-(3-chloropropyl)indazole Chemical compound C1=CC=C2N(CCCCl)N=CC2=C1 PZWAMKNKTMEYNP-UHFFFAOYSA-N 0.000 description 2
- HTQWGIHCFPWKAS-UHFFFAOYSA-N 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CNCCC11C(=O)NCN1C1=CC=CC=C1 HTQWGIHCFPWKAS-UHFFFAOYSA-N 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- NWGYRQNLZDGOQG-UHFFFAOYSA-N 2-chloro-1-(4-methylpiperidin-1-yl)ethanone Chemical compound CC1CCN(C(=O)CCl)CC1 NWGYRQNLZDGOQG-UHFFFAOYSA-N 0.000 description 2
- NSWLMOHUXYULKL-UHFFFAOYSA-N 2-chloro-1-piperidin-1-ylethanone Chemical compound ClCC(=O)N1CCCCC1 NSWLMOHUXYULKL-UHFFFAOYSA-N 0.000 description 2
- CHXZRHMQQRUVHF-UHFFFAOYSA-N 2-hex-5-en-1,3-diynyl-5-prop-1-ynylthiophene Chemical compound CC#CC1=CC=C(C#CC#CC=C)S1 CHXZRHMQQRUVHF-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- KLICRRYZSRMAMW-UHFFFAOYSA-N 2-methyl-2-[4-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CN1C(=O)C2(CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)N(C=2C=CC=CC=2)C1 KLICRRYZSRMAMW-UHFFFAOYSA-N 0.000 description 2
- KEZHRKOVLKUYCQ-UHFFFAOYSA-N 3,3-dimethyl-1h-indol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)NC2=C1 KEZHRKOVLKUYCQ-UHFFFAOYSA-N 0.000 description 2
- JDSRBSJAYLSAAA-UHFFFAOYSA-N 3-(3-chloropropyl)-1,3-benzothiazol-2-one Chemical compound C1=CC=C2SC(=O)N(CCCCl)C2=C1 JDSRBSJAYLSAAA-UHFFFAOYSA-N 0.000 description 2
- KRABBWWLDWGYGA-UHFFFAOYSA-N 3-(3-chloropropyl)-1,3-benzoxazol-2-one Chemical compound C1=CC=C2OC(=O)N(CCCCl)C2=C1 KRABBWWLDWGYGA-UHFFFAOYSA-N 0.000 description 2
- HOEUGIJCTAFMCS-UHFFFAOYSA-N 3-(3-iodopropyl)-1,3-benzoxazol-2-one Chemical compound C1=CC=C2OC(=O)N(CCCI)C2=C1 HOEUGIJCTAFMCS-UHFFFAOYSA-N 0.000 description 2
- DAPGGGKCHHQCSL-UHFFFAOYSA-N 3-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)N(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 DAPGGGKCHHQCSL-UHFFFAOYSA-N 0.000 description 2
- LWAVAWLBKZPMSS-UHFFFAOYSA-N 4-(3-chloropropyl)-1,4-benzoxazin-3-one Chemical compound C1=CC=C2N(CCCCl)C(=O)COC2=C1 LWAVAWLBKZPMSS-UHFFFAOYSA-N 0.000 description 2
- HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 2
- YMJPFUCGNNKLGS-UHFFFAOYSA-N 5-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-5-phenylpentanoic acid Chemical compound C=1C=CC=CC=1C(CCCC(=O)O)N(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 YMJPFUCGNNKLGS-UHFFFAOYSA-N 0.000 description 2
- ZIUHHJWARFFIIT-UHFFFAOYSA-N 6-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]hexanoic acid Chemical compound C1CN(CCCN2C(NC3=CC=CC=C32)=O)CCC21C(=O)N(CCCCCC(=O)O)CN2C1=CC=CC=C1 ZIUHHJWARFFIIT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N Benzylformate Chemical compound O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- QHJLPOSPWKZACG-UHFFFAOYSA-N N-Methylspiperone Chemical compound C1CN(CCCC(=O)C=2C=CC(F)=CC=2)CCC21C(=O)N(C)CN2C1=CC=CC=C1 QHJLPOSPWKZACG-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GHIQYAWTPAHVJO-UHFFFAOYSA-N [3-(3-chloropropyl)-2-oxobenzimidazol-1-yl]methyl heptanoate Chemical compound C1=CC=C2N(CCCCl)C(=O)N(COC(=O)CCCCCC)C2=C1 GHIQYAWTPAHVJO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000003936 benzamides Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 2
- DJZNTHMFEAIJOR-SANMLTNESA-N benzyl 3-[(1s)-2-methoxy-2-oxo-1-phenylethyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OCC=2C=CC=CC=2)CCC21C(=O)N([C@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 DJZNTHMFEAIJOR-SANMLTNESA-N 0.000 description 2
- WYDLASGFTGIHPB-UHFFFAOYSA-N benzyl 3-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1N1C(=O)C2(CCN(CC2)C(=O)OCC=2C=CC=CC=2)N(C=2C=CC=CC=2)C1 WYDLASGFTGIHPB-UHFFFAOYSA-N 0.000 description 2
- OTGDPPVEKSXUCQ-UHFFFAOYSA-N benzyl 3-[[3-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CC3)C(=O)OCC=3C=CC=CC=3)N(C=3C=CC=CC=3)C2)=O)=C1 OTGDPPVEKSXUCQ-UHFFFAOYSA-N 0.000 description 2
- XNAYKPAXOQHNRQ-UHFFFAOYSA-N benzyl 6-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]hexanoate Chemical compound C=1C=CC=CC=1COC(=O)CCCCCN(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 XNAYKPAXOQHNRQ-UHFFFAOYSA-N 0.000 description 2
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical group CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NXICSEVRIIPKEU-LJQANCHMSA-N methyl (2r)-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)-2-phenylacetate Chemical compound C1CNCCC21C(=O)N([C@@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 NXICSEVRIIPKEU-LJQANCHMSA-N 0.000 description 2
- NXICSEVRIIPKEU-IBGZPJMESA-N methyl (2s)-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)-2-phenylacetate Chemical compound C1CNCCC21C(=O)N([C@H](C(=O)OC)C=1C=CC=CC=1)CN2C1=CC=CC=C1 NXICSEVRIIPKEU-IBGZPJMESA-N 0.000 description 2
- YGJUJPWPXLKSEM-UHFFFAOYSA-N methyl 3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)benzoate Chemical compound COC(=O)C1=CC=CC(N2C(C3(CCNCC3)N(C=3C=CC=CC=3)C2)=O)=C1 YGJUJPWPXLKSEM-UHFFFAOYSA-N 0.000 description 2
- WPVCZAZUGWSGQB-UHFFFAOYSA-N methyl 3-[(1-oxo-4-phenyl-2,8-diazaspiro[4.5]decan-2-yl)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCNCC3)C(C=3C=CC=CC=3)C2)=O)=C1 WPVCZAZUGWSGQB-UHFFFAOYSA-N 0.000 description 2
- WPGJSAGCESKDDO-UHFFFAOYSA-N methyl 3-[1-(3-chloropropyl)indol-3-yl]propanoate Chemical compound C1=CC=C2C(CCC(=O)OC)=CN(CCCCl)C2=C1 WPGJSAGCESKDDO-UHFFFAOYSA-N 0.000 description 2
- NAAWZKWCODYWFH-UHFFFAOYSA-N methyl 3-[[1-(4-fluorophenyl)-4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(NC5=CC=CC=C54)=O)CC3)N(C=3C=CC(F)=CC=3)C2)=O)=C1 NAAWZKWCODYWFH-UHFFFAOYSA-N 0.000 description 2
- DMAPNIDVUIZHTF-UHFFFAOYSA-N methyl 3-[[1-(4-methoxyphenyl)-4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(NC5=CC=CC=C54)=O)CC3)N(C=3C=CC(OC)=CC=3)C2)=O)=C1 DMAPNIDVUIZHTF-UHFFFAOYSA-N 0.000 description 2
- GTKROSMHFKKZQX-UHFFFAOYSA-N methyl 3-[[1-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-4-phenyl-2,8-diazaspiro[4.5]decan-2-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(NC5=CC=CC=C54)=O)CC3)C(C=3C=CC=CC=3)C2)=O)=C1 GTKROSMHFKKZQX-UHFFFAOYSA-N 0.000 description 2
- BYVBJYAEFRTYPZ-UHFFFAOYSA-N methyl 3-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(NC5=CC=CC=C54)=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 BYVBJYAEFRTYPZ-UHFFFAOYSA-N 0.000 description 2
- IWZBMWBQIWYZHW-UHFFFAOYSA-N methyl 3-[[8-[4-(4-fluorophenyl)-4-oxobutyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC(=O)C=4C=CC(F)=CC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 IWZBMWBQIWYZHW-UHFFFAOYSA-N 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- JESFFJZXPJHILU-UHFFFAOYSA-N tert-butyl 1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)NCN2C1=CC=C(F)C=C1 JESFFJZXPJHILU-UHFFFAOYSA-N 0.000 description 2
- NHAKTECXIBGECS-UHFFFAOYSA-N tert-butyl 1-(4-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1=CC(OC)=CC=C1N1C2(CCN(CC2)C(=O)OC(C)(C)C)C(=O)NC1 NHAKTECXIBGECS-UHFFFAOYSA-N 0.000 description 2
- FMNXFKVTZJWOAD-UHFFFAOYSA-N tert-butyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC(C)(C)C)=CC2=C1 FMNXFKVTZJWOAD-UHFFFAOYSA-N 0.000 description 2
- PJRXWNVVGCWTJP-UHFFFAOYSA-N tert-butyl 2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1N1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 PJRXWNVVGCWTJP-UHFFFAOYSA-N 0.000 description 2
- CZZWLGQCYJDGCR-UHFFFAOYSA-N tert-butyl 2-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CBr CZZWLGQCYJDGCR-UHFFFAOYSA-N 0.000 description 2
- VOOAEMKYIJYZJU-UHFFFAOYSA-N tert-butyl 2-[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1N1C(=O)C2(CCN(CCCC(=O)C=3C=CC=CC=3)CC2)N(C=2C=CC=CC=2)C1 VOOAEMKYIJYZJU-UHFFFAOYSA-N 0.000 description 2
- UMVKZUJJPUAXKX-UHFFFAOYSA-N tert-butyl 2-[[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCC(=O)C=3C=CC=CC=3)CC2)N(C=2C=CC=CC=2)C1 UMVKZUJJPUAXKX-UHFFFAOYSA-N 0.000 description 2
- ACPYLWZBEHJFFS-UHFFFAOYSA-N tert-butyl 3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC(=O)C=4C=CC=CC=4)CC3)N(C3CCCCC3)C2)=O)=C1 ACPYLWZBEHJFFS-UHFFFAOYSA-N 0.000 description 2
- HIBCELNYZMDFCD-UHFFFAOYSA-N tert-butyl 3-[[3-[2-(dimethylamino)ethoxycarbonyl]phenyl]methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound CN(C)CCOC(=O)C1=CC=CC(CN2C(C3(CCN(CC3)C(=O)OC(C)(C)C)N(C=3C=CC=CC=3)C2)=O)=C1 HIBCELNYZMDFCD-UHFFFAOYSA-N 0.000 description 2
- FSWXPAGCMLPUOT-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-1-phenyl-8-(4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCCC=4C=CC=CC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 FSWXPAGCMLPUOT-UHFFFAOYSA-N 0.000 description 2
- WFFUYRSAPWOKOT-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(NC5=CC=CC=C54)=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 WFFUYRSAPWOKOT-UHFFFAOYSA-N 0.000 description 2
- KIYMSARUGGWLMR-UHFFFAOYSA-N tert-butyl 3-[[8-(4-hydroxy-4-phenylbutyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC(O)C=4C=CC=CC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 KIYMSARUGGWLMR-UHFFFAOYSA-N 0.000 description 2
- SESURJBVMJNDJP-UHFFFAOYSA-N tert-butyl 4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1N1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 SESURJBVMJNDJP-UHFFFAOYSA-N 0.000 description 2
- NTRSDIWGARSYRG-UHFFFAOYSA-N tert-butyl 4-[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1N1C(=O)C2(CCN(CCCC(=O)C=3C=CC=CC=3)CC2)N(C=2C=CC=CC=2)C1 NTRSDIWGARSYRG-UHFFFAOYSA-N 0.000 description 2
- CQOYPKWHYHMIGQ-UHFFFAOYSA-N tert-butyl 4-oxo-1-phenyl-3-[(3-phenylmethoxycarbonylphenyl)methyl]-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CC=1C=C(C=CC=1)C(=O)OCC=1C=CC=CC=1)CN2C1=CC=CC=C1 CQOYPKWHYHMIGQ-UHFFFAOYSA-N 0.000 description 2
- BUJOOXLJCCYFMD-UHFFFAOYSA-N tert-butyl 4-oxo-3-(6-oxo-6-phenylmethoxyhexyl)-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CCCCCC(=O)OCC=1C=CC=CC=1)CN2C1=CC=CC=C1 BUJOOXLJCCYFMD-UHFFFAOYSA-N 0.000 description 2
- OJFXLAJYAWLQTR-UHFFFAOYSA-N tert-butyl 5-chloro-3-(3-chloropropyl)-2-oxobenzimidazole-1-carboxylate Chemical compound C1=C(Cl)C=C2N(CCCCl)C(=O)N(C(=O)OC(C)(C)C)C2=C1 OJFXLAJYAWLQTR-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- IVLICPVPXWEGCA-SSDOTTSWSA-N (3s)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@H](O)CN1CC2 IVLICPVPXWEGCA-SSDOTTSWSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 150000008631 1,3,8-triazaspiro[4.5]decan-4-ones Chemical class 0.000 description 1
- QUHWFBNLVLCDLT-UHFFFAOYSA-N 1-(3-iodopropyl)-3,4-dihydrobenzimidazole-2,5-dione Chemical compound ICCCN1C(NC2=C1C=CC(C2)=O)=O QUHWFBNLVLCDLT-UHFFFAOYSA-N 0.000 description 1
- ORPVEAJIYCFESN-UHFFFAOYSA-N 1-(3-iodopropyl)-3-methylbenzimidazol-2-one Chemical compound C1=CC=C2N(CCCI)C(=O)N(C)C2=C1 ORPVEAJIYCFESN-UHFFFAOYSA-N 0.000 description 1
- KWRWFMVYODHENY-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodo-n-methoxybutan-1-imine Chemical compound ICCCC(=NOC)C1=CC=C(F)C=C1 KWRWFMVYODHENY-UHFFFAOYSA-N 0.000 description 1
- ZCNZJYVQOBYVNB-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodobutan-1-one Chemical compound FC1=CC=C(C(=O)CCCI)C=C1 ZCNZJYVQOBYVNB-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UXXLTPGCINZEFM-UHFFFAOYSA-N 1-[4-chloro-1-(4-fluorophenyl)butyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(CCCCl)C1=CC=C(F)C=C1 UXXLTPGCINZEFM-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- XILRUONFYBUYIE-UHFFFAOYSA-N 1-butyl-4-iodobenzene Chemical compound CCCCC1=CC=C(I)C=C1 XILRUONFYBUYIE-UHFFFAOYSA-N 0.000 description 1
- GLGLVWBYIFIRJI-UHFFFAOYSA-N 1-cyclohexyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CNCCC11C(=O)NCN1C1CCCCC1 GLGLVWBYIFIRJI-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- JXKLHMBKHMYCBS-UHFFFAOYSA-N 2-[4-oxo-8-[3-(2-oxo-3H-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)N(C(C12CCN(CCCN3C4=CC=CC=C4CC3=O)CC2)=O)CN1C1=CC=CC=C1 JXKLHMBKHMYCBS-UHFFFAOYSA-N 0.000 description 1
- CQQUWTMMFMJEFE-UHFFFAOYSA-N 2-chloro-n,n-diethylacetamide Chemical compound CCN(CC)C(=O)CCl CQQUWTMMFMJEFE-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- AORVPBLZSJVLCI-UHFFFAOYSA-N 3,3-difluoro-1h-indol-2-one Chemical compound C1=CC=C2C(F)(F)C(=O)NC2=C1 AORVPBLZSJVLCI-UHFFFAOYSA-N 0.000 description 1
- WNKPOMBPWFBOJH-UHFFFAOYSA-N 3,4-dihydro-1H-benzimidazole-2,5-dione Chemical compound N1C(NC2=C1C=CC(C2)=O)=O WNKPOMBPWFBOJH-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- MERTXFWGALCWFT-UHFFFAOYSA-N 3-(1h-indol-3-yl)propyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCC1=CNC2=CC=CC=C12 MERTXFWGALCWFT-UHFFFAOYSA-N 0.000 description 1
- VOHKKFVJAXANPR-UHFFFAOYSA-N 3-(3-chloropropyl)-2h-indazole Chemical compound C1=CC=C2C(CCCCl)=NNC2=C1 VOHKKFVJAXANPR-UHFFFAOYSA-N 0.000 description 1
- MZSGZXMPNBPPOM-UHFFFAOYSA-N 3-(3-hydroxypropyl)-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(CCCO)C(=O)NC2=C1 MZSGZXMPNBPPOM-UHFFFAOYSA-N 0.000 description 1
- PAXSXGYJPKPWJQ-UHFFFAOYSA-N 3-(3-iodopropyl)-1h-indole Chemical compound C1=CC=C2C(CCCI)=CNC2=C1 PAXSXGYJPKPWJQ-UHFFFAOYSA-N 0.000 description 1
- QYLFKNVZIFTCIY-UHFFFAOYSA-N 3-(bromomethyl)-2,3-dihydro-1,4-benzodioxine Chemical compound C1=CC=C2OC(CBr)COC2=C1 QYLFKNVZIFTCIY-UHFFFAOYSA-N 0.000 description 1
- BBZCPUCZKLTAJQ-UHFFFAOYSA-N 3-methyloxindole Chemical compound C1=CC=C2C(C)C(=O)NC2=C1 BBZCPUCZKLTAJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- MMYDPFZYBDKMHH-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)-n-methoxybutan-1-imine Chemical compound ClCCCC(=NOC)C1=CC=C(F)C=C1 MMYDPFZYBDKMHH-UHFFFAOYSA-N 0.000 description 1
- NGBTWDPPZFGUAY-UHFFFAOYSA-N 4-chloro-1-(4-methoxyphenyl)butan-1-one Chemical compound COC1=CC=C(C(=O)CCCCl)C=C1 NGBTWDPPZFGUAY-UHFFFAOYSA-N 0.000 description 1
- YPESHVNOQBCGSQ-UHFFFAOYSA-N 4-iodo-1-thiophen-2-ylbutan-1-one Chemical compound ICCCC(=O)C1=CC=CS1 YPESHVNOQBCGSQ-UHFFFAOYSA-N 0.000 description 1
- LQNMGMMOHCDYPF-UHFFFAOYSA-N 4-iodobutylbenzene Chemical compound ICCCCC1=CC=CC=C1 LQNMGMMOHCDYPF-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
- QIGIQLYKEULMQQ-UHFFFAOYSA-N 5-chloro-1,3-dihydrobenzimidazol-2-one Chemical compound ClC1=CC=C2NC(=O)NC2=C1 QIGIQLYKEULMQQ-UHFFFAOYSA-N 0.000 description 1
- PBGMZDKEQJHNQB-UHFFFAOYSA-N 5-chloro-3-(3-chloropropyl)-1h-benzimidazol-2-one Chemical compound ClC1=CC=C2NC(=O)N(CCCCl)C2=C1 PBGMZDKEQJHNQB-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QHJWZRAZVIBJOL-UHFFFAOYSA-N C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCN4C5=CC=CC=C5C(C4=O)(F)F Chemical compound C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCN4C5=CC=CC=C5C(C4=O)(F)F QHJWZRAZVIBJOL-UHFFFAOYSA-N 0.000 description 1
- FQJJCVJOKGZTCL-UHFFFAOYSA-N CC(C)(C)C(NC(C12CCNCC1)=O)N2C1=CC=CC=C1 Chemical compound CC(C)(C)C(NC(C12CCNCC1)=O)N2C1=CC=CC=C1 FQJJCVJOKGZTCL-UHFFFAOYSA-N 0.000 description 1
- BVHOLCCRVFFQOH-UHFFFAOYSA-N CCOC(CCCN(C(C(C)(C)C)N(C12CCNCC1)C1=CC=CC=C1)C2=O)=O Chemical compound CCOC(CCCN(C(C(C)(C)C)N(C12CCNCC1)C1=CC=CC=C1)C2=O)=O BVHOLCCRVFFQOH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
- 229940088353 Dopamine D3 receptor antagonist Drugs 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 101150097070 Drd3 gene Proteins 0.000 description 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010052211 Oesophageal rupture Diseases 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010066962 Procedural nausea Diseases 0.000 description 1
- 206010066963 Procedural vomiting Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZMNJVPDJHSNAJP-UMSFTDKQSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 3-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CC=CC=1CN(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 ZMNJVPDJHSNAJP-UMSFTDKQSA-N 0.000 description 1
- ZMNJVPDJHSNAJP-UUWRZZSWSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] 3-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CC=CC=1CN(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 ZMNJVPDJHSNAJP-UUWRZZSWSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003994 anesthetic gas Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000007860 aryl ester derivatives Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- BLVISDBEMWCEGZ-UHFFFAOYSA-N benzyl 1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1=CC(F)=CC=C1N1C2(CCN(CC2)C(=O)OCC=2C=CC=CC=2)C(=O)NC1 BLVISDBEMWCEGZ-UHFFFAOYSA-N 0.000 description 1
- VVBVWCUYUMZBIR-UHFFFAOYSA-N benzyl 1-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CC2(C(NCN2C2CCCCC2)=O)CCN1C(=O)OCC1=CC=CC=C1 VVBVWCUYUMZBIR-UHFFFAOYSA-N 0.000 description 1
- FYLLRVVMRRVMMP-NDEPHWFRSA-N benzyl 3-[(1s)-2-[(2-methylpropan-2-yl)oxy]-2-oxo-1-phenylethyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OCC=2C=CC=CC=2)CCC21C(=O)N([C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)CN2C1=CC=CC=C1 FYLLRVVMRRVMMP-NDEPHWFRSA-N 0.000 description 1
- HTOSBRSWLOAYOZ-UHFFFAOYSA-N benzyl 6-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)hexanoate Chemical compound C=1C=CC=CC=1COC(=O)CCCCCN(C(C12CCNCC2)=O)CN1C1=CC=CC=C1 HTOSBRSWLOAYOZ-UHFFFAOYSA-N 0.000 description 1
- CRQXYWRYKDAOKA-UHFFFAOYSA-N benzyl 6-bromohexanoate Chemical compound BrCCCCCC(=O)OCC1=CC=CC=C1 CRQXYWRYKDAOKA-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- SGDINNZGYDHHKM-UHFFFAOYSA-N dilithium;trimethylsilylazanide Chemical compound [Li+].[Li+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] SGDINNZGYDHHKM-UHFFFAOYSA-N 0.000 description 1
- IBJITZQNEZOOCS-UHFFFAOYSA-L dipotassium methylsulfinylmethane carbonate Chemical compound [K+].[K+].CS(C)=O.[O-]C([O-])=O IBJITZQNEZOOCS-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 description 1
- GNTQPOKMAQQMDK-UHFFFAOYSA-N ethyl 1-[(3,4-dichlorophenyl)carbamoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)NC1=CC=C(Cl)C(Cl)=C1 GNTQPOKMAQQMDK-UHFFFAOYSA-N 0.000 description 1
- UKHFDJNDUMOQTQ-UHFFFAOYSA-N ethyl 4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)butanoate Chemical compound C1CNCCC21C(=O)N(CCCC(=O)OCC)CN2C1=CC=CC=C1 UKHFDJNDUMOQTQ-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- UCVODTZQZHMTPN-UHFFFAOYSA-N heptanoyl chloride Chemical compound CCCCCCC(Cl)=O UCVODTZQZHMTPN-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 108010024941 iodothyronine deiodinase type II Proteins 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- QKASDIPENBEWBU-UHFFFAOYSA-N methyl 2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CBr QKASDIPENBEWBU-UHFFFAOYSA-N 0.000 description 1
- XWYXOGRYGWNOSD-UHFFFAOYSA-N methyl 2-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 XWYXOGRYGWNOSD-UHFFFAOYSA-N 0.000 description 1
- BXXLTVBTDZXPTN-UHFFFAOYSA-N methyl 2-iodobenzoate Chemical compound COC(=O)C1=CC=CC=C1I BXXLTVBTDZXPTN-UHFFFAOYSA-N 0.000 description 1
- BAYIDMGOQRXHBC-UHFFFAOYSA-N methyl 3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(CCC(=O)OC)=CNC2=C1 BAYIDMGOQRXHBC-UHFFFAOYSA-N 0.000 description 1
- UAGBZATTYPWSGF-UHFFFAOYSA-N methyl 3-[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-3-phenylpropanoate Chemical compound C=1C=CC=CC=1C(CC(=O)OC)N(C(C12CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)=O)CN1C1=CC=CC=C1 UAGBZATTYPWSGF-UHFFFAOYSA-N 0.000 description 1
- XGYJOJUOIBCWMZ-UHFFFAOYSA-N methyl 3-[[1-(4-methoxyphenyl)-4-oxo-8-[3-(2-oxo-1,3-benzothiazol-3-yl)propyl]-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(SC5=CC=CC=C54)=O)CC3)N(C=3C=CC(OC)=CC=3)C2)=O)=C1 XGYJOJUOIBCWMZ-UHFFFAOYSA-N 0.000 description 1
- QBIHBTJWLPENMG-UHFFFAOYSA-N methyl 3-[[4-oxo-8-[3-(2-oxo-1,3-benzothiazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(SC5=CC=CC=C54)=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 QBIHBTJWLPENMG-UHFFFAOYSA-N 0.000 description 1
- GDMKIKJKFKPKQT-UHFFFAOYSA-N methyl 3-[[8-[3-(1h-indol-3-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC=4C5=CC=CC=C5NC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 GDMKIKJKFKPKQT-UHFFFAOYSA-N 0.000 description 1
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
- VPLFDLHKQRTWJY-UHFFFAOYSA-N methyl 4-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 VPLFDLHKQRTWJY-UHFFFAOYSA-N 0.000 description 1
- MSEBQGULDWDIRW-UHFFFAOYSA-N methyl 4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1 MSEBQGULDWDIRW-UHFFFAOYSA-N 0.000 description 1
- BUSBVSKBYJTICU-UHFFFAOYSA-N methyl 5-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)-5-phenylpentanoate Chemical compound C=1C=CC=CC=1C(CCCC(=O)OC)N(C(C12CCNCC2)=O)CN1C1=CC=CC=C1 BUSBVSKBYJTICU-UHFFFAOYSA-N 0.000 description 1
- PCKHBNYMLHPLCO-UHFFFAOYSA-N methyl 5-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)pentanoate Chemical compound C1CNCCC21C(=O)N(CCCCC(=O)OC)CN2C1=CC=CC=C1 PCKHBNYMLHPLCO-UHFFFAOYSA-N 0.000 description 1
- VFDHOEUTMYIPMF-UHFFFAOYSA-N methyl 5-bromo-5-phenylpentanoate Chemical compound COC(=O)CCCC(Br)C1=CC=CC=C1 VFDHOEUTMYIPMF-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- VBQDDGKJLPYWLD-UHFFFAOYSA-N n-[3-[[4-oxo-8-[3-(2'-oxospiro[cyclopropane-1,3'-indole]-1'-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5C5(CC5)C4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 VBQDDGKJLPYWLD-UHFFFAOYSA-N 0.000 description 1
- RSOHSYBKAHXLKI-UHFFFAOYSA-N n-[3-[[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5CC4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 RSOHSYBKAHXLKI-UHFFFAOYSA-N 0.000 description 1
- UNQQSUDSBHPBOI-UHFFFAOYSA-N n-[4-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-2-yl)methyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC1N(C=2C=CC=CC=2)C2(CCNCC2)C(=O)N1 UNQQSUDSBHPBOI-UHFFFAOYSA-N 0.000 description 1
- JHQCLTNJUMEILJ-UHFFFAOYSA-N n-[4-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 JHQCLTNJUMEILJ-UHFFFAOYSA-N 0.000 description 1
- USWHDTMQQNUPNS-UHFFFAOYSA-N n-[4-[4-oxo-8-[3-(2'-oxospiro[cyclopropane-1,3'-indole]-1'-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N1C(=O)C2(CCN(CCCN3C4=CC=CC=C4C4(CC4)C3=O)CC2)N(C=2C=CC=CC=2)C1 USWHDTMQQNUPNS-UHFFFAOYSA-N 0.000 description 1
- PEORUGKEOKVUKJ-UHFFFAOYSA-N n-[4-[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N1C(=O)C2(CCN(CCCN3C4=CC=CC=C4CC3=O)CC2)N(C=2C=CC=CC=2)C1 PEORUGKEOKVUKJ-UHFFFAOYSA-N 0.000 description 1
- CVECYTFRDLPOKH-UHFFFAOYSA-N n-[4-[8-[3-(3,3-dimethyl-2-oxoindol-1-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]phenyl]methanesulfonamide Chemical compound C12=CC=CC=C2C(C)(C)C(=O)N1CCCN(CC1)CCC1(C1=O)N(C=2C=CC=CC=2)CN1C1=CC=C(NS(C)(=O)=O)C=C1 CVECYTFRDLPOKH-UHFFFAOYSA-N 0.000 description 1
- UAJMUICSJWQWHY-UHFFFAOYSA-N n-[4-[8-[4-(4-fluorophenyl)-4-oxobutyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N1C(=O)C2(CCN(CCCC(=O)C=3C=CC(F)=CC=3)CC2)N(C=2C=CC=CC=2)C1 UAJMUICSJWQWHY-UHFFFAOYSA-N 0.000 description 1
- JJNIAECEWPEQGG-UHFFFAOYSA-N n-[4-[[4-oxo-8-(4-oxo-4-phenylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CN1C(=O)C2(CCN(CCCC(=O)C=3C=CC=CC=3)CC2)N(C=2C=CC=CC=2)C1 JJNIAECEWPEQGG-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- LBBWIBWOPGDMAJ-UHFFFAOYSA-N spiro[1h-indole-3,1'-cyclopropane]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CC1 LBBWIBWOPGDMAJ-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZOMWUUKMYMDFB-OAQYLSRUSA-N tert-butyl (2r)-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)-2-phenylacetate Chemical compound C1CNCCC21C(=O)N([C@@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)CN2C1=CC=CC=C1 VZOMWUUKMYMDFB-OAQYLSRUSA-N 0.000 description 1
- VZOMWUUKMYMDFB-NRFANRHFSA-N tert-butyl (2s)-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)-2-phenylacetate Chemical compound C1CNCCC21C(=O)N([C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)CN2C1=CC=CC=C1 VZOMWUUKMYMDFB-NRFANRHFSA-N 0.000 description 1
- NXEMHHPFETVDLI-YTTGMZPUSA-N tert-butyl (2s)-2-[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-2-phenylacetate Chemical compound C1CN(CCCN2C3=CC=CC=C3CC2=O)CCC21C(=O)N([C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)CN2C1=CC=CC=C1 NXEMHHPFETVDLI-YTTGMZPUSA-N 0.000 description 1
- XBVKVILRIZBDER-UHFFFAOYSA-N tert-butyl 1-(3-chloropropyl)indole-2-carboxylate Chemical compound C1=CC=C2N(CCCCl)C(C(=O)OC(C)(C)C)=CC2=C1 XBVKVILRIZBDER-UHFFFAOYSA-N 0.000 description 1
- GRSSCMGPPGPQIB-UHFFFAOYSA-N tert-butyl 2-[4-(hydroxymethyl)phenoxy]-2-methylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)OC1=CC=C(CO)C=C1 GRSSCMGPPGPQIB-UHFFFAOYSA-N 0.000 description 1
- GOVUKXWHLVETAW-UHFFFAOYSA-N tert-butyl 2-[[1-(4-fluorophenyl)-4-oxo-8-[3-(2'-oxospiro[cyclopropane-1,3'-indole]-1'-yl)propyl]-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCN3C4=CC=CC=C4C4(CC4)C3=O)CC2)N(C=2C=CC(F)=CC=2)C1 GOVUKXWHLVETAW-UHFFFAOYSA-N 0.000 description 1
- PZTYBENDPVXAPJ-UHFFFAOYSA-N tert-butyl 2-[[4-oxo-8-[3-(2'-oxospiro[cyclopropane-1,3'-indole]-1'-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCN3C4=CC=CC=C4C4(CC4)C3=O)CC2)N(C=2C=CC=CC=2)C1 PZTYBENDPVXAPJ-UHFFFAOYSA-N 0.000 description 1
- WQLLBHMASGSCKJ-UHFFFAOYSA-N tert-butyl 2-[[8-[3-(3-cyclopropyl-2-oxobenzimidazol-1-yl)propyl]-1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCN3C(N(C4CC4)C4=CC=CC=C43)=O)CC2)N(C=2C=CC(F)=CC=2)C1 WQLLBHMASGSCKJ-UHFFFAOYSA-N 0.000 description 1
- TXJIMBREBIGOHX-UHFFFAOYSA-N tert-butyl 2-[[8-[3-(3-cyclopropyl-2-oxobenzimidazol-1-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCN3C(N(C4CC4)C4=CC=CC=C43)=O)CC2)N(C=2C=CC=CC=2)C1 TXJIMBREBIGOHX-UHFFFAOYSA-N 0.000 description 1
- GGWYCKVTPBUJMP-UHFFFAOYSA-N tert-butyl 2-[[8-[3-(3-fluoro-3-methyl-2-oxoindol-1-yl)propyl]-1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CCCN3C4=CC=CC=C4C(C)(F)C3=O)CC2)N(C=2C=CC(F)=CC=2)C1 GGWYCKVTPBUJMP-UHFFFAOYSA-N 0.000 description 1
- ANNQWFNGFLLCGS-UHFFFAOYSA-N tert-butyl 2-methyl-2-[4-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)methyl]phenoxy]propanoate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2(CCNCC2)N(C=2C=CC=CC=2)C1 ANNQWFNGFLLCGS-UHFFFAOYSA-N 0.000 description 1
- BJTOGLTUTBDRAV-UHFFFAOYSA-N tert-butyl 2-methyl-2-[4-[[4-oxo-8-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]phenoxy]propanoate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2(CCN(CCCN3C(NC4=CC=CC=C43)=O)CC2)N(C=2C=CC=CC=2)C1 BJTOGLTUTBDRAV-UHFFFAOYSA-N 0.000 description 1
- QSWHKTWATXJYTR-UHFFFAOYSA-N tert-butyl 3-(4-ethoxy-4-oxobutyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CCCC(=O)OCC)CN2C1=CC=CC=C1 QSWHKTWATXJYTR-UHFFFAOYSA-N 0.000 description 1
- HFPVIJDLODNQLJ-UHFFFAOYSA-N tert-butyl 3-(5-methoxy-5-oxo-1-phenylpentyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C=1C=CC=CC=1C(CCCC(=O)OC)N(C(C12CCN(CC2)C(=O)OC(C)(C)C)=O)CN1C1=CC=CC=C1 HFPVIJDLODNQLJ-UHFFFAOYSA-N 0.000 description 1
- RVUREYVAQSGYBP-UHFFFAOYSA-N tert-butyl 3-(5-methoxy-5-oxopentyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CCCCC(=O)OC)CN2C1=CC=CC=C1 RVUREYVAQSGYBP-UHFFFAOYSA-N 0.000 description 1
- RAKUACRTGOPEEG-UHFFFAOYSA-N tert-butyl 3-[(2-methoxycarbonylphenyl)methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound COC(=O)C1=CC=CC=C1CN1C(=O)C2(CCN(CC2)C(=O)OC(C)(C)C)N(C=2C=CC=CC=2)C1 RAKUACRTGOPEEG-UHFFFAOYSA-N 0.000 description 1
- PLMDLGHWEGDECJ-UHFFFAOYSA-N tert-butyl 3-[(4-methoxycarbonylphenyl)methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)C2(CCN(CC2)C(=O)OC(C)(C)C)N(C=2C=CC=CC=2)C1 PLMDLGHWEGDECJ-UHFFFAOYSA-N 0.000 description 1
- HOPCBHKSKRROGN-UHFFFAOYSA-N tert-butyl 3-[[3-(1-methylpiperidin-4-yl)oxycarbonylphenyl]methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C)CCC1OC(=O)C1=CC=CC(CN2C(C3(CCN(CC3)C(=O)OC(C)(C)C)N(C=3C=CC=CC=3)C2)=O)=C1 HOPCBHKSKRROGN-UHFFFAOYSA-N 0.000 description 1
- PALNMCNMDPBJMP-UHFFFAOYSA-N tert-butyl 3-[[3-(2-morpholin-4-ylethoxycarbonyl)phenyl]methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CC=1C=C(C=CC=1)C(=O)OCCN1CCOCC1)CN2C1=CC=CC=C1 PALNMCNMDPBJMP-UHFFFAOYSA-N 0.000 description 1
- RVFUTCKOJDDVIB-QFIPXVFZSA-N tert-butyl 3-[[3-[(2s)-butan-2-yl]oxycarbonylphenyl]methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound CC[C@H](C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CC3)C(=O)OC(C)(C)C)N(C=3C=CC=CC=3)C2)=O)=C1 RVFUTCKOJDDVIB-QFIPXVFZSA-N 0.000 description 1
- LZNORDHDCHNCSD-UHFFFAOYSA-N tert-butyl 3-[[3-[2-(diethylamino)-2-oxoethoxy]carbonylphenyl]methyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound CCN(CC)C(=O)COC(=O)C1=CC=CC(CN2C(C3(CCN(CC3)C(=O)OC(C)(C)C)N(C=3C=CC=CC=3)C2)=O)=C1 LZNORDHDCHNCSD-UHFFFAOYSA-N 0.000 description 1
- HZGGTCFRLKHVPH-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-8-(4-oxo-4-thiophen-2-ylbutyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC(=O)C=4SC=CC=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 HZGGTCFRLKHVPH-UHFFFAOYSA-N 0.000 description 1
- RBULVMAJAXFZMJ-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-8-[3-(2'-oxospiro[cyclopropane-1,3'-indole]-1'-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5C5(CC5)C4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 RBULVMAJAXFZMJ-UHFFFAOYSA-N 0.000 description 1
- CDFDJNRMIGEKEG-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5CC4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 CDFDJNRMIGEKEG-UHFFFAOYSA-N 0.000 description 1
- XNCPSWZYESYOJQ-UHFFFAOYSA-N tert-butyl 3-[[4-oxo-8-[3-(3-oxo-1,4-benzoxazin-4-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5OCC4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 XNCPSWZYESYOJQ-UHFFFAOYSA-N 0.000 description 1
- NNOBKWNKIGYSGN-UHFFFAOYSA-N tert-butyl 3-[[8-[3-(2h-indazol-3-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCC=4C5=CC=CC=C5NN=4)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 NNOBKWNKIGYSGN-UHFFFAOYSA-N 0.000 description 1
- MCOLLLWRGIDXMR-UHFFFAOYSA-N tert-butyl 3-[[8-[3-(3,3-difluoro-2-oxoindol-1-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5C(F)(F)C4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 MCOLLLWRGIDXMR-UHFFFAOYSA-N 0.000 description 1
- IMSFGOYWMADGKT-UHFFFAOYSA-N tert-butyl 3-[[8-[3-(3,3-dimethyl-2-oxoindol-1-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C5=CC=CC=C5C(C)(C)C4=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 IMSFGOYWMADGKT-UHFFFAOYSA-N 0.000 description 1
- KIHYSDUUBJGORL-UHFFFAOYSA-N tert-butyl 3-[[8-[3-(3-cyclopropyl-2-oxobenzimidazol-1-yl)propyl]-1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(N(C5CC5)C5=CC=CC=C54)=O)CC3)N(C=3C=CC(F)=CC=3)C2)=O)=C1 KIHYSDUUBJGORL-UHFFFAOYSA-N 0.000 description 1
- TXQQSTZMNZLZIA-UHFFFAOYSA-N tert-butyl 3-[[8-[3-(3-cyclopropyl-2-oxobenzimidazol-1-yl)propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CN2C(C3(CCN(CCCN4C(N(C5CC5)C5=CC=CC=C54)=O)CC3)N(C=3C=CC=CC=3)C2)=O)=C1 TXQQSTZMNZLZIA-UHFFFAOYSA-N 0.000 description 1
- ZCHJPBQBPRFJMI-UHFFFAOYSA-N tert-butyl 3-[[8-[3-[3-(3-methoxy-3-oxopropyl)indol-1-yl]propyl]-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound C12=CC=CC=C2C(CCC(=O)OC)=CN1CCCN(CC1)CCC1(C1=O)N(C=2C=CC=CC=2)CN1CC1=CC=CC(C(=O)OC(C)(C)C)=C1 ZCHJPBQBPRFJMI-UHFFFAOYSA-N 0.000 description 1
- BNTWYIQQOQGFAO-UHFFFAOYSA-N tert-butyl 4-(5-chloro-2-oxo-3h-benzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)NC2=CC(Cl)=CC=C21 BNTWYIQQOQGFAO-UHFFFAOYSA-N 0.000 description 1
- GSIBTIUXYYFCPU-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CBr)C=C1 GSIBTIUXYYFCPU-UHFFFAOYSA-N 0.000 description 1
- QIIKHUKFPGIKPU-UHFFFAOYSA-N tert-butyl 4-[[4-oxo-8-[3-(2-oxo-3h-indol-1-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2(CCN(CCCN3C4=CC=CC=C4CC3=O)CC2)N(C=2C=CC=CC=2)C1 QIIKHUKFPGIKPU-UHFFFAOYSA-N 0.000 description 1
- YSLSTRDDSINWKZ-UHFFFAOYSA-N tert-butyl 4-oxo-3-[[3-(2-oxo-2-piperidin-1-ylethoxy)carbonylphenyl]methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CC=1C=C(C=CC=1)C(=O)OCC(=O)N1CCCCC1)CN2C1=CC=CC=C1 YSLSTRDDSINWKZ-UHFFFAOYSA-N 0.000 description 1
- FQYAYLGIKTZELO-UHFFFAOYSA-N tert-butyl 5-chloro-2-oxo-3h-benzimidazole-1-carboxylate Chemical compound C1=C(Cl)C=C2NC(=O)N(C(=O)OC(C)(C)C)C2=C1 FQYAYLGIKTZELO-UHFFFAOYSA-N 0.000 description 1
- CRAQTQCTGGCBBK-UHFFFAOYSA-N tert-butyl 6-chloro-2-oxo-3h-benzimidazole-1-carboxylate Chemical compound ClC1=CC=C2NC(=O)N(C(=O)OC(C)(C)C)C2=C1 CRAQTQCTGGCBBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
本発明は、仮出願(出願番号61/356,096;出願日2010年6月18日)の優先権を主張するものであり、該仮出願の内容は本明細書の一部を構成する。
本発明の一態様は、式I:
[式中、
R1は以下からなる群:
場合により3位がシクロプロピルで置換されている、または6位が塩素で置換されている(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)(C2−C4アルキル)、
(2−オキソベンゾ[d]オキサゾール−3(2H)−イル)(C2−C4アルキル)、
(2−オキソベンゾ[d]チアゾール−3(2H)−イル)(C2−C4アルキル)、
場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)(C2−C4アルキル)、
(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))(C2−C4アルキル)、
(2−オキソインドリン−3−イル))(C2−C4アルキル)、
フェニル(C1−C6アルキル)、
1−ヒドロキシ−1−フェニルメチル(C2−C6 アルキル)、
1−アセトキシオキシ−1−フェニルメチル(C2−C6 アルキル)、
ビス(4−フルオロフェニル)メチル−(C1−C6アルキル)、
(1H−ベンゾ[d][1,2,3]トリアゾール−1−イル)(C2−C4アルキル)、
場合によりフェニルの4位がハロで置換されている1−フェニル−1−オキソ−(C2−C6アルキル)、
2,3−ジヒドロベンゾ[b][1,4]ジオキサン−2−(C2−C4アルキル)、
1−(チオフェン−2−イル)−1−オキソ−(C1−C6アルキル)、
3−オキソ−2H−ベンゾ[b][1,4]オキサジン−4−イル−(C2−C4アルキル)、
(2−(シクロアルキル)−1H−ベンゾ[d]イミダゾール−1−イル)(C2−C4アルキル)、
((3−((C1−C6アルキル)カルボニルオキシ(メチル))−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
((3−(メトキシカルボニルエチル)−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
((2−(t-ブトキシカルボニル)−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
1H−インダゾール−3−イル(C2−C4アルキル)、
(1−(インドリン−1−イル)−1−オキソ)(C2−C4アルキル)、
((3−(C1−C6アルキル)オキシカルボニル(C1−C6アルキル))−1H−インドール−1−イル)(C2−C4アルキル)、または
(2−(C1−C6アルキル)オキシカルボニル−1H−インドール−1−イル)(C2−C4アルキル)から選択され;
R2は、クロロ、フルオロまたはメトキシで場合によりパラ置換されているフェニル、直鎖または分岐鎖のC2−C6アルキル、場合により1〜6のハロゲンで置換されている3〜7炭素原子シクロアルキルであり;および
R3は、
R10はHまたは1〜6炭素のアルキルである]
で示される化合物またはその製薬的に許容し得る塩、またはその異性体である。
一態様では、本発明は式I:
[式中、
R1は以下からなる群:
場合により3位がシクロプロピルで置換されている、または6位が塩素で置換されている(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)(C2−C4アルキル)、
(2−オキソベンゾ[d]オキサゾール−3(2H)−イル)(C2−C4アルキル)、
(2−オキソベンゾ[d]チアゾール−3(2H)−イル)(C2−C4アルキル)、
場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)(C2−C4アルキル)、
(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))(C2−C4アルキル)、
(2−オキソインドリン−3−イル))(C2−C4アルキル)、
フェニル(C1−C6アルキル)、
1−ヒドロキシ−1−フェニルメチル(C2−C6 アルキル)、
1−アセトキシオキシ−1−フェニルメチル(C2−C6 アルキル)、
ビス(4−フルオロフェニル)メチル−(C1−C6アルキル)、
(1H−ベンゾ[d][1,2,3]トリアゾール−1−イル)(C2−C4アルキル)、
場合によりフェニルの4位がハロで置換されている1−フェニル−1−オキソ−(C2−C6アルキル)、
2,3−ジヒドロベンゾ[b][1,4]ジオキサン−2−(C2−C4アルキル)、
1−(チオフェン−2−イル)−1−オキソ−(C1−C6アルキル)、
3−オキソ−2H−ベンゾ[b][1,4]オキサジン−4−イル))(C2−C4アルキル)、
(2−(シクロアルキル)−1H−ベンゾ[d]イミダゾール−1−イル)(C2−C4アルキル)、
((3−((C1−C6アルキル)カルボニルオキシ(メチル))−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
((3−(メトキシカルボニルエチル)−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
((2−(t-ブトキシカルボニル)−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
1H−インダゾール−3−イル(C2−C4アルキル)、
(1−(インドリン−1−イル)−1−オキソ)(C2−C4アルキル)、
((3−(C1−C6アルキル)オキシカルボニル(C1−C6アルキル))−1H−インドール−1−イル)(C2−C4アルキル)、または
(2−(C1−C6アルキル)オキシカルボニル−1H−インドール−1−イル)(C2−C4アルキル)
から選択され;
R2は、クロロ、フルオロまたはメトキシで場合によりパラ置換されているフェニル、直鎖または分岐鎖のC2−C6アルキル、場合により1〜6のハロゲンで置換されている3〜7炭素原子シクロアルキルであり;および
R3は、
R10はHまたは1〜6炭素のアルキルである]
で示される化合物またはその製薬的に許容し得る塩、またはその異性体を提供する。
R1が、場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)プロピル、(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))プロピル、(2−オキソインドリン−3−イル))プロピル、または場合により4位がハロで置換されている1−フェニル−1−オキソ−プロピルであり;
化合物6(実施例2) メチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物7(実施例3) メチル 5−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ペンタノエート
化合物8(実施例4) エチル 4−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ブタノエート
化合物11(実施例5) 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物13(実施例6) メチル 5−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−5−フェニルペンタノエート
化合物14(実施例7) メチル 2−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物15(実施例8) メチル 4−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物16(実施例9) 2−(ジメチルアミノ)エチル3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物17(実施例10) 4−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物18(実施例11)(S)−sec−ブチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物19(実施例12) 2−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物20(実施例13) 1−メチルピペリジン−4−イル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物21(実施例14) ベンジル 6−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ヘキサノエート
化合物22(実施例15) 6−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ヘキサン酸
化合物24(実施例16) 2−(ジメチルアミノ)−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物25(実施例17) 2−モルホリノエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物26(実施例18)(R)−キヌクリジン−3−イル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物30(実施例19) 2−(ジエチルアミノ)−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物31(実施例20) 2−アミノ−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物32(実施例21) 2−オキソ−2−(ピペリジン−1−イル)エチル3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物33(実施例22)(S)−メチル 2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニルアセテート
化合物34(実施例23)(R)−メチル 2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニルアセテート
化合物35(実施例24) 2−(4−メチルピペリジン−1−イル)−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物39(実施例25)(R)−2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
化合物40(実施例26)(S)−2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
化合物42(実施例27) メチル 3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物43(実施例28) 3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物45(実施例29)(S)−キヌクリジン−3−イル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物46(実施例30) メチル 3−((4−オキソ−8−(3−(2−オキソベンゾ[d]オキサゾール−3(2H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物47(実施例31) メチル 3−((4−オキソ−8−(3−(2−オキソベンゾ[d]チアゾール−3(2H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物48(実施例32) メチル 3−((8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物49(実施例33) 3−((8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物50(実施例34) メチル 3−((8−(3−(3−メチル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物52(実施例35) 3−((4−オキソ−8−(3−(2−オキソベンゾ[d]チアゾール−3(2H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物55(実施例36) メチル 3−((1−(4−メトキシフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物56(実施例37) 3−((1−(4−メトキシフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物57(実施例38) メチル 3−((8−(3−(1H−インドール−3−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物58(実施例39) 3−((8−(3−(3−メチル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物59(実施例40) 3−((8−(3−(1H−インドール−3−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物60(実施例41) tert−ブチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物61(実施例42) tert−ブチル 3−((8−(3−(3−(ヘプタノイルオキシメチル)−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物62(実施例43) tert−ブチル 3−((1−シクロヘキシル−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物64(実施例44) ベンジル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物69(実施例45) 5−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−5−フェニルペンタン酸
化合物70(実施例46) 3−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−3−フェニルプロパン酸
化合物71(実施例47) 3−((4−オキソ−8−(3−(3−オキソ−2H−ベンゾ[b][1,4]オキサジン−4(3H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物72(実施例48) 3−((1−シクロヘキシル−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, ホルメート
化合物74(実施例49) 3−((8−(ヘプタノイルオキシメチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, ホルメート
化合物76(実施例50) 3−((8−((2,3−ジヒドロベンゾ[b][1,4]ジオキシン−2−イル)メチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物77(実施例51) 3−((8−(4,4−(4−フルオロフェニル)ブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物82(実施例52) 3−((1−(4−メトキシフェニル)−4−オキソ−8−(3−(2−オキソベンゾ[d]チアゾール−3(2H)−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物82(実施例53) 3−((8−(3−(1H−インダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物83(実施例54) メチル 3−((1−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−フェニル-2,8−ジアザスピロ[4.5]デカン−2−イル)メチル)ベンゾエート
化合物85(実施例55) 3−((8−(3−(1H−ベンゾ[d][1,2,3]トリアゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物89(実施例56) 3−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物91(実施例57) 3−((8−(4−(4−メトキシフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物92(実施例58) tert−ブチル 3−((8−(3−(3,3−ジフルオロ−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物93(実施例59) tert−ブチル 3−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物94(実施例60) 3−((8−(3−(3,3−ジフルオロ−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物100(実施例61) 3−((8−(3−(6−クロロ−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物102(実施例62) 2−メチル−2−(4−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェノキシ)プロパン酸
化合物108(実施例63) tert−ブチル 3−((8−(3−(1H−インダゾール−3−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物110(実施例64) 3−((8−(3−(2−(tert−ブトキシカルボニル)−1H−インドール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物120(実施例65) 3−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物123(実施例66) 3−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物126(実施例67) 3−((8−(3−(3−(3−メトキシ−3−オキソプロピル)−1H−インドール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物130(実施例68) 3−((4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物131(実施例69) 3−((4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物137(実施例70) 2−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物138(実施例71) 3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物142(実施例72) 3−((4−オキソ−1−フェニル−8−(4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, ホルメート
化合物143(実施例73) 3−((4−オキソ−8−(4−オキソ−4−(チオフェン−2−イル)ブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物145(実施例74) 3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物146(実施例75) 3−((8−(3−(3−メチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物148(実施例76) 2−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物149(実施例77) 2−((4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物150(実施例78) 3−((1−シクロヘキシル−8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物153(実施例79) 2−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物153(実施例80) 2−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物154(実施例81) 2−((4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物155(実施例82) 2−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物156(実施例83) 3−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物157(実施例84) 3−((8−(4−(4−フルオロフェニル)−4−(メトキシイミノ)ブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物158(実施例85) 3−((1−(4−フルオロフェニル)−4−オキソ−8−(4−オキソ−4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物159(実施例86) 2−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物160(実施例87) 3−((4−オキソ−8−(3−(2−オキソインドリン−3−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物161(実施例88) 2−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物162(実施例89) 2−((8−(3−(3−フルオロ−3−メチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物163(実施例90) 2−((8−(3−(3−フルオロ−3−メチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物164(実施例91) 3−((8−(3−(3−フルオロ−3−メチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物166(実施例92)(R)−2−(4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
化合物167(実施例93)(R)−2−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
化合物168(実施例94)(S)−2−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
化合物170(実施例95)(S)−2−(4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
化合物171(実施例96) 4−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物172(実施例97) 4−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物173(実施例98) 3−((8−(4−ヒドロキシ−4−フェニルブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
化合物176(実施例99) 3−((1−シクロヘキシル−4−オキソ−8−(4−オキソ−4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
化合物177(実施例100) 3−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート
化合物179(実施例101) メチル 3−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート
化合物180(実施例102) 2−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート
化合物182(実施例103) 4−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート, 塩酸塩
化合物186(実施例104) N−(4−((4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
化合物211(実施例105) N−(3−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
化合物212(実施例106) N−(3−((4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
化合物213(実施例107) N−(3−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
化合物214(実施例108) N−(4−(8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
化合物215(実施例109) N−(4−(4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
化合物216(実施例110) N−(4−(4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
化合物217(実施例111) N−(4−(8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド.
化合物218(実施例112) 2−((1−シクロヘキシル−4−オキソ−8−(4−オキソ−4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
消化管の運動機能は、迷走神経と筋層間神経叢によってコントロールされる抑制および刺激プロセスの相互作用を必要とする。胃内容排出遅延の一翼を担うと考えられる抑制メカニズムはドーパミン受容体の刺激である。ドーパミンD2および/またはD3受容体への刺激は、胃底の弛緩を増大し、蠕動が減少し、胃の緊張を減少させ、胃と十二指腸との間の収縮作用の調整が損なわれる。また、ドーパミン自体も吐き気や嘔吐を引き起こし得る脳の領域内の受容体を刺激する。
本明細書に記載した新規な化合物が定義されれば、本発明の技術に基づき、本発明の化合物を以下の標準的な化学反応により調製される。
スキームIは、N1(シクロ)アルキルもしくはアリールR2基、R3基を含むN3 アルキルまたはアリール カルボン酸、およびN8(ヘテロ)アリールアルキルR1基を有する、1,3,8−トリアザスピロ[4.5] デカン−4−オン環系の構築を示したものである。N1の置換基は、25℃〜50℃にて、適当なR2−置換アミンアミン、N−ベンジル−4−ピペリドン、シアン化ナトリウムまたはトリメチルシリルシアニド等のシアニド源、およびアルコールまたは混合水性アルコール溶媒中の塩酸またはp-トルエンスルホン酸等の酸のStrecker反応により導入して、α−アミノニトリル(1)を得る。アミノニトリル(1)は、25℃〜50℃にて、濃スルホン酸に添加した後、水相での処理と塩基による中和により、最も便利に加水分解され、アミノカルボキサミド(2)が得られる。アミノカルボキサミド(2)は、3〜10当量のトリエチルオルトホルメートおよび1〜5当量のギ酸または酢酸等の有機酸とともに100℃〜150℃に加熱することにより環化することができる。あるいは、アミノカルボキサミド(2)は、硫酸等の強酸の存在下で、過剰量のホルムアミドとともに加熱することにより環化して、1,3,8−トリアザスピロ[4.5]デカン−2−エン−4−オン(3)を得ることができる。1,3,8−トリアザスピロ[4.5]デカン−2−エン−4−オン(3)は、25℃〜50℃にて、エタノール等のアルコール溶媒中、水素化ホウ素ナトリウムで還元してN−ベンジル保護の1,3,8−トリアザスピロ[4.5]デカン−4−オン(4)を得ることができる。酢酸エチルまたはアルコール溶媒中、パラジウム等の金属触媒の存在下での水素化により、ピペリジン窒素を脱離して(5)を得ることができる。あるいは、1,3,8−トリアザスピロ[4.5]デカン−2−エン−4−オン(3)を、パラジウム等の金属触媒およびエタノール中の塩酸等の酸触媒の存在下、60 psiでの水素化により、脱ベンジル化1,3,8−トリアザスピロ[4.5]デカン−4−オン(5)に直接変換することもできる。1,3,8−トリアザスピロ[4.5]デカン−4−オン(5)は、ジクロロメタン中クロロぎ酸ベンジルとピリジンを用いて、カルバメート(6)に変換することができる。N,N−ジメチルホルムアミド等の極性非プロトン溶媒中、炭酸カリウムまたはリチウム ビス(トリメチルシリルアミド)の存在下、25℃から50℃にて、カルバメート(6)と適当に保護されたハロアルキル(アリール)エステル(例えば, PG =メチルまたは t−ブチル)との反応により、N3置換基を導入して(7)を得ることができる。あるいは、N3置換基がフェニルまたはアリールエステル基である場合には、Buchwald'sのプロトコルを用いる必要があるかもしれない。この場合、アセトニトリル中、ヨウ化銅、ジメチルエチレンジアミン、および炭酸カリウムの存在下、75℃にて、カルバメート(6)をアルキルヨードベンゾエートと反応させて(7)を得ることができる。酢酸エチルまたはアルコール溶媒中、パラジウム等の金属触媒の存在下、大気圧にて水素化することによりカルバメート(7)を脱保護して、脱保護された1,3,8−トリアザスピロ[4.5]デカン−4−オン(8)を得ることができる。アセトンまたは2−ブタノン等の適当な溶媒中、炭酸カリウム等の塩基、0.1〜1当量のヨウ化ナトリウム触媒の存在下、50℃〜80℃にて、(8)と適当な(ヘテロ)アリール アルキルハライドまたはトシラートとを反応させることによりN8置換基を導入して、完全に置換された1,3,8−トリアザスピロ[4.5]デカン−4−オン(9)を得ることができる。(9)のエステル保護基がt−ブチル基である場合、ジオキサン中の塩酸またはジクロロエタン中の20〜50%トリフルオロ酢酸等の強酸で処理して脱保護し、カルボン酸(10)をトリフルオロ酢酸塩として得ることができる。(9)のエステル保護基がメチルまたはエチル基である場合、水性メタノール中、水酸化リチウムで処理した後、酢酸で慎重に中和してカルボン酸(10)を得ることができる。この一般的な記載の具体例は本明細書に記載する。
本明細書に記載するように、1,3,8−トリアザスピロ[4.5]デカン−4−オンコア構造のR1, R2およびR3置換基はそれらの系統的化学名によって記述する。本発明の説明上、R1は1,3,8−トリアザスピロ[4.5]デカン−4−オンコア構造の8位で置換され、R2は1位で置換され、R3置換基は3位に存在する。例えば、ここに記載するR1置換の一例は、2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピルである。その系統的名称により定義される化学構造は以下のとおりである:
本明細書中の用語「C1−C6アルキル」は、「C1−C6」および「アルキル」との間にスペースを入れた用語(「C1−C6アルキル」)と同意義であるとする。本発明の一態様では、R1の位置のアルキル連結基はC2−C4アルキル、即ち、エチル、プロピルまたはブチルである。
場合により3位がシクロプロピルで置換されるか、または6位が塩素で置換されている、(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)(C1−C4アルキル) (後者の場合を下に示す)
ドーパミンD2受容体の親和性をin vitroで試験した。以下にヒトD2受容体を発現する細胞系の構築、ならびに結合試験について記載する。
ヒトD2 受容体 は、短いタイプ(D2S)と長いタイプ(D2L)の2つのアイソフォームが存在する。この2つのアイソフォームはD2遺伝子から別々のスプライシングによって作製され、D2Lアイソフォームは、タンパク質構造の第3の分子内ループのさらなる29アミノ酸を有する点でD2Sアイソフォームと異なる。
セルカルチャー
HEK293細胞を、5% CO2雰囲気下、37℃にて、10% FBS、0.292 g/liter L-グルタミン、105 units/liter ペニシリン、100 mg/liter ストレプトマイシンおよび500mg/ml ジェネティシンを添加したイーグル最小必須培地に維持した。細胞を80〜90%コンフルエントまで増殖させ、cell stripper(Cellgro #25−056−CI)で細胞を回収した。次いで、細胞をPBS(2X)で洗浄した。細胞をペレット化するか−80℃で凍結するか、あるいは即座に膜を調製した。
ペレット化した細胞をホモジネート化バッファー(15mM Tris*HCl, 2mM MgCl2*6H2O, 0.3mM EDTA, 1mM EGTA pH 7.4 @ 4℃)に再懸濁した。次いで、細胞をPolytron(PT 1200)ホモジナイザー(10秒を6セット)を用いてホモジナイズした。粗製の膜を39, 412gで15分間4℃(2X)にてSorval RC6 plus遠心分離機でペレット化した。最終的に、膜を再懸濁バッファー(50mM Tris*HCl, 120mM NaCl, 10mM MgCl2*6H2O,1mM EDTA pH 7.4 @ 4℃)に再懸濁し、超音波処理(Fisher Sonic Dismembrator)を10秒間5セットおこなった。
最終容量を1.0mLとし、マイクロタイタープレート(Costar #3961)にて放射性リガンド結合試験を行った。
放射性リガンドのKDは既知(0.09nM)なので、各化合物の阻害解離定数(Ki)をCheng & Prusoffの方法(Cheng, Y-C and Prusoff(1973)Biochem Pharmacol., 22: 3099−3108)に従い決定した。
PTLC = 分取薄層クロマトグラフィー
メチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
室温で3時間攪拌した後、反応混合物を減圧濃縮してメチル3−((4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエートを塩酸塩として得た。
MS for C32H35N5O4
m/z 554.12 (M+H)+.
60℃で60時間攪拌した後、反応混合物を酢酸エチル(25 mL)で希釈し、希クエン酸、水およびブラインで洗浄した。有機相をMgSO4で乾燥し、濾過し、濃縮して黄褐色の固形物(0.2 g, 93%)を得た; 1H NMR(DMSO−d6): δ1.45(s,9H)、1.64(d, 2H, J = 13.6 Hz)、2.41−2.49(m,2H)、3.48(br, 2H)、3.85(s,3H)、3.86−3.90(m,2H)、4.59−4.64(m,4H)、6.68(d, 2H, J = 8.4 Hz)、6.77(t, 1H, J = 7.4 Hz)、7.17(t, 2H, J = 8 Hz)、7.54−7.60(m,2H)、7.89−7.92(m,2H);
MS for C27H33N3O5
m/z 480.08 (M+H)+.
MS for C18H25N3O3
m/z 332.04 (M+H)+.
メチル 5−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ペンタノエート
MS for C29H37N5O4
m/z 520.11 (M+H)+.
MS for C24H35N3O5
m/z 446.09 (M+H)+.
エチル 4−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ブタノエート
MS for C29H37N5O4
m/z 520.15 (M+H)+.
3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N5O4
m/z 540.07 (M+H)+.
MS for C35H41N5O4
m/z 596 (M+H)+.
MS for C33H37N3O5
m/z 556.07 (M+H)+.
MS for C21H23N3O3
m/z 366 (M+H)+.
メチル 5−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−5−フェニルペンタノエート
MS for C35H41N5O4
m/z 596.06 (M+H)+.
メチル 2−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H35N5O4
m/z 554.05 (M+H)+.
MS for C27H33N3O5
m/z 480.04 (M+H)+.
メチル 4−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H35N5O4
m/z 554.05 (M+H)+.
MS for C27H33N3O5
m/z 480.04 (M+H)+.
2−(ジメチルアミノ)エチル3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C35H42N6O4
m/z 611.10 (M+H)+.
MS for C30H40N4O5
m/z 537 (M+H)+.
4−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N5O4
m/z 540.05 (M+H)+.
(S)−sec−ブチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C35H41N5O4
m/z 596.13 (M+H)+.
MS for C30H39N3O5
m/z 544.05(M+Na)+.
2−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N5O4
m/z 540.01 (M+H)+.
1−メチルピペリジン−4−イル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C37H44N6O4
m/z 637.22 (M+H)+.
MS for C32H42N4O5
m/z 563.06 (M+H)+.
ベンジル 6−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ヘキサノエート
MS for C36H43N5O4
m/z 610.12 (M+H)+.
MS for C31H41N3O5
m/z 536.16 (M+H)+.
6−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ヘキサン酸
MS for C29H37N5O4
m/z 520.08 (M+H)+.
2−(ジメチルアミノ)−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C35H40N6O5
m/z 625.05 (M+H)+.
MS for C30H38N4O6
m/z 551.04 (M+H)+.
2−モルホリノエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C37H44N6O5
m/z 653.09 (M+H)+.
MS for C32H42N4O6
m/z 579.09 (M+H)+.
(R)−キヌクリジン−3−イル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C38H44N6O4
m/z 649.11 (M+H)+.
2−(ジエチルアミノ)−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C37H44N6O5
m/z 653.08 (M+H)+.
MS for C32H42N4O6
m/z 579.10 (M+H)+.
2−アミノ−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H36N6O5
m/z 597.01 (M+H)+.
MS for C28H34N4O6
m/z 523.04 (M+H)+.
2−オキソ−2−(ピペリジン−1−イル)エチル3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C38H44N6O5
m/z 665.17 (M+H)+.
MS for C33H42N4O6
m/z 591.08 (M+H)+.
(S)−メチル 2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニルアセテート
MS for C32H35N5O4
m/z 554.11 (M+H)+.
MS for C9H9BrO2
m/z 229.98 (M+H)+.
MS for C27H33N3O5
m/z 479.57 (M+H)+.
MS for C22H25N3O3
m/z 380.01 (M+H)+.
(R)−メチル 2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニルアセテート
MS for C32H35N5O4
m/z 554.07 (M+H)+.
MS for C9H9BrO2
m/z 229.98 (M+H)+.
MS for C27H33N3O5
m/z 479.57 (M+H)+.
MS for C22H25N3O3
m/z 380.03 (M+H)+.
2−(4−メチルピペリジン−1−イル)−2−オキソエチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C38H45N7O5
m/z 680.17 (M+H)+.
MS for C33H43N5O6
m/z 606.08 (M+H)+.
(R)−2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
MS for C31H33ClN5O4 540.01 (M+H)+.
MS for C32H35N5O4
m/z 554.07 (M+H)+.
MS for C9H9BrO2
m/z 229.98 (M+H)+.
MS for C27H33N3O5
m/z 479.57 (M+H)+.
MS for C22H25N3O3
m/z 380.03 (M+H)+.
(S)−2−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
MS for C31H33ClN5O4
m/z 540.07 (M+H)+.
MS for C32H35N5O4
m/z 554.11 (M+H)+.
MS for C9H9BrO2
m/z 229.98 (M+H)+.
MS for C27H33N3O5
m/z 479.57 (M+H)+.
MS for C22H25N3O3
m/z 399.93 (M+H)+.
メチル 3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34FN5O4
m/z 572.07 (M+H)+.
3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H32FN5O4
m/z 558.02 (M+H)+.
(S)−キヌクリジン−3−イル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C38H44N6O4
m/z 649.11 (M+H)+.
メチル 3−((4−オキソ−8−(3−(2−オキソベンゾ[d]オキサゾール−3(2H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34N4O5
m/z 555.05 (M+H)+.
MS for C10H10INO2
m/z 304.33 (M+H)+.
メチル 3−((4−オキソ−8−(3−(2−オキソベンゾ[d]チアゾール−3(2H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34N4O4S
m/z 571.05 (M+H)+.
メチル 3−((8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34FN3O4
m/z 544.02 (M+H)+.
MS for C27H33N3O5
m/z 479.24 (M+H)+.
MS for C22H25N3O3
m/z 379.19 (M+H)+.
MS for C10H10FIO
m/z 291.98 (M+H)+.
3−((8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H32FN3O4
m/z 529.99 (M+H)+.
メチル 3−((8−(3−(3−メチル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H37N5O4
m/z 568.13 (M+H)+.
MS for C11H13ClN2O
m/z 226.07 (M+H)+.
MS for C11H13IN2O
m/z 316.89 (M+H)+.
3−((4−オキソ−8−(3−(2−オキソベンゾ[d]チアゾール−3(2H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H32N4O4S
m/z 556.95 (M+H)+.
メチル 3−((1−(4−メトキシフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H37N5O5
m/z 584.04 (M+H)+.
MS for C28H35N3O6
m/z 510.01 (M+H)+.
3−((1−(4−メトキシフェニル)−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H35N5O5
m/z 570.04 (M+H)+.
メチル 3−((8−(3−(1H−インドール−3−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H36N4O3
m/z 537.06 (M+H)+.
MS for C11H12IN
m/z 285.12 (M+H)+.
3−((8−(3−(3−メチル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H35N5O4
m/z 554.05 (M+H)+.
3−((8−(3−(1H−インドール−3−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34N4O3
m/z 523.07 (M+H)+.
tert−ブチル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C35H41N5O4
m/z 596.16 (M+H)+.
tert−ブチル 3−((8−(3−(3−(ヘプタノイルオキシメチル)−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C43H55N5O6
m/z 738 (M+H)+.
MS for C21H23N3O3
m/z 366.18 (M+H)+.
MS for C33H37N3O5
m/z 556.28 (M+H)+.
MS for C25H31N3O3
m/z 422.24 (M+H)+.
MS for C18H25ClN2O3
m/z 353 (M+H)+.
MS for C11H13ClN2O2
m/z 241 (M+H)+.
tert−ブチル 3−((1−シクロヘキシル−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C35H47N5O4
m/z 602 (M+H)+.
MS for C25H37N3O3
m/z 428 (M+H)+.
MS for C33H43N3O5
m/z 562 (M+H)+.
実施例44 化合物64
ベンジル 3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
この塩酸塩と炭酸カリウム(1.68 g, 12.15 mmol)のN,N−ジメチルホルムアミド(20 mL)溶液に、1−(3−ヨードプロピル)−1,3−ジヒドロ−2H−ベンズイミダゾール−2−オン(1.47 g, 4.86 mmol)を加えた。55℃で18時間攪拌した後、反応混合物を酢酸エチル(100 mL)で希釈し、水及びブラインで洗浄した。有機相をMgSO4で乾燥し、濾過し、濃縮し、Biotage フラッシュクロマトグラフィー(2−20% メタノール/ジクロロメタン)により単離し、生成物を得た(2.6 g, 88%); 1H NMR(DMSO−d6): δ1.55(d, 2H, J = 13.2 Hz)、1.82(t, 2H, J = 6.4 Hz)、2.33(t, 2H, J = 6.8 Hz)、2.50-2.59(m,6H)、3.85(t, 2H, J = 6.8 Hz)、4.59(d, 4H, J = 16.8 Hz)、5.32(s,2H)、6.76(t, 1H, J = 7.2 Hz)、6.83(d, 2H, J = 8 Hz)、6.96(d, 3H, J = 1.2 Hz)、7.18−7.24(m,3H)、7.31−7.36(m,3H)、7.42(dd, 2H, J = 7.6 and 1.6 Hz)、7.52−7.59(m,2H)、7.86(s,1H)、7.91−7.94(m,1H)、10.83(s,1H);
MS for C38H39N5O4
m/z 630.14 (M+H)+.
5−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−5−フェニルペンタン酸
MS for C34H39N5O4
m/z 582.12 (M+H)+.
3−(4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−3−フェニルプロパン酸
MS for C32H35N5O4
m/z 554.05 (M+H)+.
3−((4−オキソ−8−(3−(3−オキソ−2H−ベンゾ[b][1,4]オキサジン−4(3H)−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34N4O5
m/z 555.06 (M+H)+.
MS for C36H42N4O5
m/z 611.12 (M+H)+.
MS for C11H12ClNO2
m/z 225.96 (M+H)+.
3−((1−シクロヘキシル−4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, ホルメート
MS for C31H39N5O4
m/z 546 (M+H)+.
3−((8−(ヘプタノイルオキシメチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, ホルメート
MS for C29H37N3O5
m/z 508 (M+H)+.
3−((8−((2,3−ジヒドロベンゾ[b][1,4]ジオキシン−2−イル)メチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C30H31N3O5
m/z 513.99 (M+H)+.
MS for C34H39N3O5
m/z 570.12 (M+H)+.
3−((8−(4,4−(4−フルオロフェニル)ブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C37H37F2N3O3
m/z 610.18 (M+H)+.
MS for C41H45F2N3O3
m/z 666.18 (M+H)+.
3−((1−(4−メトキシフェニル)−4−オキソ−8−(3−(2−オキソベンゾ[d]チアゾール−3(2H)−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34N4O5S
m/z 587.02 (M+H)+.
MS for C33H36N4O5S
m/z 601.04 (M+H)+.
3−((8−(3−(1H−インダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N5O3
m/z 524.06 (M+H)+.
MS for C35H41N5O3
m/z 580.14 (M+H)+.
MS for C10H11ClN2
m/z 195.00 (M+H)+.
メチル 3−((1−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−フェニル-2,8−ジアザスピロ[4.5]デカン−2−イル)メチル)ベンゾエート
MS for C33H36N4O4
m/z 553.11 (M+H)+.
MS for C23H26N2O3
m/z 379.2 (M+H)+.
MS for C31H32N2O5
m/z 513.23 (M+H)+.
3−((8−(3−(1H−ベンゾ[d][1,2,3]トリアゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C30H32N6O3
m/z 525.08 (M+H)+.
MS for C34H40N6O3
m/z 581.20 (M+H)+.
MS for C9H10ClN3
m/z 196.01 (M+H)+.
3−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C32H34N4O4
m/z 539 (M+H)+.
MS for C36H42N4O4
m/z 595 (M+H)+.
MS for C11H12ClNO
m/z 210 (M+H)+.
3−((8−(4−(4−メトキシフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H35N3O5
m/z 542.02 (M+H)+.
MS for C36H43N3O5
m/z 598.3 (M+H)+.
MS for C11H13ClO2
m/z 214.1 (M+H)+.
tert−ブチル 3−((8−(3−(3,3−ジフルオロ−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C36H40F2N4O4
m/z 631.11 (M+H)+.
MS for C11H10ClF2NO
m/z 247.01 (M+H)+.
tert−ブチル 3−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C38H46N4O4
m/z 623.18 (M+H)+.
MS for C13H16ClNO
m/z 237.99 (M+H)+.
3−((8−(3−(3,3−ジフルオロ−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H32F2N4O4
m/z 575.03 (M+H)+.
3−((8−(3−(6−クロロ−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H32ClN5O4
m/z 574 (M+H)+.
MS for C35H40ClN5O4
m/z 630.15 (M+H)+.
MS for C12H13ClN2O3
m/z 268.94 (M+H)+.
MS for C15H18Cl2N2O3
m/z 346.1 (M+H)+.
MS for C10H10Cl2N2O
m/z 244.93 (M+H)+.
2−メチル−2−(4−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェノキシ)プロパン酸
MS for C34H39N5O5
m/z 598.21 (M+H)+.
MS for C38H47N5O5
m/z 654.18 (M+H)+.
MS for C36H43N3O6
m/z 614.15 (M+H)+.
tert−ブチル 3−((8−(3−(1H−インダゾール−3−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N5O3
m/z 524.07 (M+H)+.
MS for C35H41N5O3
m/z 580.13 (M+H)+.
3−((8−(3−(2−(tert−ブトキシカルボニル)−1H−インドール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C37H42N4O5
m/z 623.16 (M+H)+.
MS for C44H48N4O5
m/z 713.37 (M+H)+.
MS for C33H37N3O5
m/z 556.27 (M+H)+.
tert−ブチル 3−(3−(ベンジルオキシカルボニル)ベンジル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−8−カルボキシレート(913 mg, 1.646 mmol, 1当量)の4M塩酸ジオキサン溶液を室温で4.5時間攪拌した。この混合物を減圧濃縮し、残留物を凍結乾燥して標題化合物の塩酸塩をクリーム色の固形物として得た(747 mg, 定量的);
MS for C28H29N3O3
m/z 456.04 (M+H)+.
MS for C13H15NO2
m/z 217.99 (M+H)+.
MS for C16H20ClNO2
m/z 293.12 (M+H)+.
3−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H37N5O4
m/z 580.13 (M+H)+.
MS for C38H45N5O4
m/z 636.26 (M+H)+.
MS for C13H15ClN2O
m/z 251.02 (M+H)+.
3−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H37FN4O4
m/z 585.23 (M+H)+.
MS for C33H36FN3O5
m/z 574.11 (M+H)+.
3−((8−(3−(3−(3−メトキシ−3−オキソプロピル)−1H−インドール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C36H40N4O5
m/z 609 (M+H)+.
MS for C40H48N4O5
m/z 665 (M+H)+.
MS for C15H18ClNO2
m/z 280 (M+H)+.
3−((4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C34H36N4O4
m/z 565 (M+H)+.
MS for C38H44N4O4
m/z 621 (M+H)+.
3−((4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N3O4
m/z 512.07 (M+H)+.
MS for C35H41N3O4
m/z 568.16 (M+H)+.
2−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H38N4O4
m/z 567.22 (M+H)+.
MS for C38H46N4O4
m/z 623.28 (M+H)+.
MS for C33H37N3O5
m/z 556.12 (M+H)+.
MS for C13H16ClNO
m/z 237.99 (M+H)+.
3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H35FN4O4
m/z 583.16 (M+H)+.
MS for C38H43FN4O4
m/z 639.14 (M+H)+.
MS for C13H14ClNO
m/z 236.04 (M+H)+.
3−((4−オキソ−1−フェニル−8−(4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, ホルメート
MS for C31H35N3O3
m/z 498 (M+H)+.
MS for C35H43N3O3
m/z 554 (M+H)+.
3−((4−オキソ−8−(4−オキソ−4−(チオフェン−2−イル)ブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C29H31N3O4S
m/z 518 (M+H)+.
MS for C33H39N3O4S
m/z 574 (M+H)+.
MS for C8H9IOS
m/z 281 (M+H)+.
3−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H33FN4O4
m/z 557.09 (M+H)+.
MS for C11H12ClNO
m/z 210.03 (M+H)+.
3−((8−(3−(3−メチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H36N4O4
m/z 553.11 (M+H)+.
MS for C37H44N4O4
m/z 609.3 (M+H)+.
MS for C12H14ClNO
m/z 211.06 (M+H)+.
2−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H34N4O4
m/z 539.15 (M+H)+.
2−((4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H36N4O4
m/z 565.14 (M+H)+.
MS for C38H44N4O4
m/z 621.12 (M+H)+.
3−((1−シクロヘキシル−8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C31H38FN3O4
m/z 536 (M+H)+.
MS for C35H46FN3O4
m/z 592 (M+H)+.
2−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C32H33FN4O4
m/z 557.06 (M+H)+.
MS for C36H41FN4O4
m/z 613.15 (M+H)+.
MS for C33H36FN3O5
m/z 596.12(M+Na)+.
2−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H37FN4O4
m/z 585.11 (M+H)+.
MS for C38H45FN4O4
m/z 641.17 (M+H)+.
2−((4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H33N3O4
m/z 512.4 (M+H)+.
MS for C35H41N3O4
m/z 568.31 (M+H)+.
MS for C10H11IO
m/z 274.99 (M+H)+.
2−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H37N5O4
m/z 580.12 (M+H)+.
MS for C38H45N5O4
m/z 636.12 (M+H)+.
3−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H36FN5O4
m/z 598.28 (M+H)+.
MS for C38H44FN5O4
m/z 654.24 (M+H)+.
3−((8−(4−(4−フルオロフェニル)−4−(メトキシイミノ)ブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C32H35FN4O4
m/z 559 (M+H)+.
MS for C36H43FN4O4
m/z 615 (M+H)+.
MS for C11H13FNO
m/z 322 (M+H)+.
MS for C11H13ClFNO
m/z 230 (M+H)+.
3−((1−(4−フルオロフェニル)−4−オキソ−8−(4−オキソ−4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H32FN3O4
m/z 530.4 (M+H)+.
MS for C35H40FN3O4
m/z 586.5 (M+H)+.
2−((8−(3−(3−シクロプロピル−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H36FN5O4
m/z 598.4 (M+H)+.
MS for C38H44FN5O4
m/z 654.34 (M+H)+.
3−((4−オキソ−8−(3−(2−オキソインドリン−3−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C32H34N4O4
m/z 539 (M+H)+.
MS for C36H42N4O4
m/z 595 (M+H)+.
MS for C12H15NO4S
m/z 270 (M+H)+.
メチル3−インドールプロピオネート(5.00 g, 0.0246 mol)、酢酸(10 mL)、ジメチルスルホキシド(26 mL, 0.369 mol, 15 eq.)および濃塩酸(37%)(22 mL, 0.738 mol, 30 eq.)の混合物を室温で2.5時間攪拌した。水を混合物に加え、混合物を酢酸エチルで抽出した。有機層をMgSO4で乾燥し、濾過し、減圧濃縮した。粗製の残留物をBiotageフラッシュクロマトグラフィーシステム(30% 酢酸エチル/ヘキサン)を用いて精製し、標題の化合物を油として得た(5.28 g, 98%); 1H NMR(DMSO−d6); δ2.03−2.10(m,2H); 2.32−2.39(m,2H); 3.46(t, J = 6.4 Hz, 1H); 3.54(s,3H); 6.81(d, J = 7.6 Hz, 1H); 6.93−6.97(m,1H); 7.15−7.17(m,1H); 7.24(d, J = 7.6 Hz, 1H);
実施例88 化合物161
2−((1−(4−フルオロフェニル)−4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C34H35FN4O4
m/z 583.3 (M+H)+.
MS for C38H43FN4O4
m/z 639.4 (M+H)+.
2−((8−(3−(3−フルオロ−3−メチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H35FN4O4
m/z 571.3 (M+H)+.
MS for C37H43FN4O4
m/z 627.4 (M+H)+.
2−((8−(3−(3−フルオロ−3−メチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H34F2N4O4
m/z 589.3 (M+H)+.
MS for C37H42F2N4O4
m/z 645.3 (M+H)+.
3−((8−(3−(3−フルオロ−3−メチル−2−オキソインドリン−1−イル)プロピル)−1−(4−フルオロフェニル)−4−オキソ−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C33H34F2N4O4
m/z 589.3 (M+H)+.
MS for C37H42F2N4O4
m/z 645.5 (M+H)+.
(R)−2−(4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
MS for C32H34N4O4
m/z 539 (M+H)+.
MS for C36H42N4O4
m/z 595.32 (M+H)+.
(R)−2−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
MS for C31H33N3O4
m/z 512.3 (M+H)+.
MS for C35H41N3O4
m/z 568.4 (M+H)+.
(S)−2−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
MS for C31H33N3O4
m/z 512.4 (M+H)+.
MS for C35H41N3O4
m/z 568.4 (M+H)+.
MS for C9H9BrO2
m/z 229.98 (M+H)+.
MS for C30H31N3O5
m/z 514.23 (M+H)+.
MS for C29H29N3O5
m/z 500.21 (M+H)+.
MS for C33H37N3O5
m/z 556.28 (M+H)+.
MS for C25H31N3O3
m/z 422.24 (M+H)+.
(S)−2−(4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)−2−フェニル酢酸
MS for C32H34N4O4
m/z 539.4 (M+H)+.
4−((8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C34H38N4O4
m/z 567 (M+H)+.
MS for C38H46N4O4
m/z 623 (M+H)+.
MS for C25H31N3O3
m/z 422 (M+H)+.
リチウム tert−ブトキシド(ヘキサン中1M, 178 mL, 0.178 mol)を室温で p-トルオイルクロリド(25 g, 0.162 mol)のテトラヒドロフラン溶液(150 mL)に滴加した。この混合物を室温で一晩攪拌した後、水で希釈し酢酸エチルで抽出した。抽出物をブラインで洗浄し、乾燥(MgSO4)し、留去し、生成物を、静置すると結晶化する油として得た(31 g, 98%)
4−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C32H34N4O4
m/z 539 (M+H)+.
MS for C36H42N4O4
m/z 595 (M+H)+.
3−((8−(4−ヒドロキシ−4−フェニルブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
MS for C31H35N3O4
m/z 514.4 (M+H)+.
MS for C35H43N3O4
m/z 570.33 (M+H)+.
3−((1−シクロヘキシル−4−オキソ−8−(4−オキソ−4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C31H39N3O4
m/z 518 (M+H)+.
MS for C35H47N3O4
m/z 574 (M+H)+.
3−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート
MS for C30H31N3O4
m/z 498 (M+H)+.
メチル 3−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート
MS for C31H33N3O4
m/z 512.3 (M+H)+.
2−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート
MS for C30H31N3O4
m/z 498.3 (M+H)+.
MS for C34H39N3O4
m/z 554.3 (M+H)+.
MS for C24H29N3O3
m/z 408.22 (M+H)+.
MS for C32H35N3O5
m/z 542.26 (M+H)+.
MS for C28H27N3O5
m/z 486.3 (M+H)+.
MS for C29H29N3O5
m/z 500.21 (M+H)+.
4−(4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)ベンゾエート, 塩酸塩
MS for C30H31N3O4
m/z 498 (M+H)+.
MS for C34H39N3O4
m/z 554 (M+H)+.
MS for C24H29N3O3
m/z 408 (M+H)+.
MS for C32H35N3O5
m/z 542 (M+H)+.
MS for C28H27N3O5
m/z 486 (M+H)+.
MS for C29H29N3O5
m/z 500 (M+H)+.
N−(4−((4−オキソ−8−(4−オキソ−4−フェニルブチル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
MS for C31H36N4O4S
m/z 561 (M+H)+.
MS for C21H26N4O3S
m/z 415 (M+H)+.
MS for C26H34N4O5S
m/z 515 (M+H)+.
MS for C25H32N4O3
m/z 437 (M+H)+.
MS for C25H30N4O5
m/z 467 (M+H)+.
N−(3−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
MS for C30H33FN4O4S
m/z 565.3 (M+H)+.
N−(3−((4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
N−(3−((4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド(0.2 g, 0.48 mmol)、ヨウ化ナトリウム(0.029 g, 0.19 mmol)および炭酸カリウム(0.133 g, 0.96 mmol)の2−ブタノン(5 mL)溶液に、1'−(3−クロロプロピル)スピロ[シクロプロパン−1,3'-インドリン]−2'−オン(0.114 g, 0.48 mmol)を加えた。78℃で18時間攪拌した後、反応混合物を濾過し、分取TLC(10% メタノール/ジクロロメタン)により単離して標題の化合物を得た(0.09 g, 31%); 1H NMR(DMSO−d6): δ1.51(t, 2H, J = 3.6 Hz)、1.58(t, 2H, J = 3.6 Hz)、1.64(d, 2H, J = 13.2 Hz)、1.80(br, 2H)、2.37(br, 2H)、2.51−2.57(m,2H)、2.68−2.73(m,4H)、2.96(s,3H)、3.82(t, 2H, J = 6.8 Hz)、4.52(s,2H)、4.58(s,2H)、6.76(t, 1H, J = 7.6 Hz)、6.84(d, 2H, J = 8.4 Hz)、6.96−7.02(m,3H)、7.09(s,1H)、7.12(d, 1H, J = 8 Hz)、7.17−7.24(m,4H)、7.32(t, 1H, J = 8 Hz)、9.81(s,1H);
MS for C34H39N5O4S
m/z 614.4 (M+H)+.
冷却した(0℃)、ベンジル 3−(3−ニトロベンジル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−8−カルボキシレート(0.8 g, 1.7 mmol)およびピリジン(0.275 mL, 3.4 mmol, d = 0.978)のジクロロメタン(20 mL)溶液に、メタンスルホニルクロリド(0.12 mL, 1.53 mmol, d = 1.48)を加えた。室温で18時間攪拌した後、反応混合物を希クエン酸、水およびブラインで洗浄した。有機相をMgSO4で乾燥し、濾過し、Biotageフラッシュクロマトグラフィー(10−100% 酢酸エチル/ヘキサン)で単離して標題の化合物を得た(0.83 g, 89%); 1H NMR(DMSO−d6): δ1.73(d, 2H, J = 13.6 Hz)、2.35−2.43(m,2H)、2.97(s,3H)、3.57(br, 2H)、4.00-4.05(m,2H)、4.55(s,2H)、4.61(s,2H)、5.13(br, 2H)、6.88(d, 2H, J = 8 Hz)、6.76(t, 1H, J = 7.6 Hz)、7.03(d, 1H, J = 7.6 Hz)、7.10-7.20(m,4H)、7.31−7.39(m,6H)、9.80(s,1H);
MS for C29H32N4O5S
m/z 549.3 (M+H)+.
MS for C28H28N4O5
m/z 501.3 (M+H)+.
N−(3−((4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)フェニル)メタンスルホンアミド
MS for C32H37N5O4S
m/z 588.3 (M+H)+.
N−(4−(8−(4−(4−フルオロフェニル)−4−オキソブチル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
MS for C30H33FN4O4S
m/z 565.3 (M+H)+.
MS for C25H32N4O5S
m/z 501.3 (M+H)+.
N−(4−(4−オキソ−8−(3−(2−オキソインドリン−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
MS for C31H35N5O4S
m/z 574 (M+H)+.
N−(4−(4−オキソ−8−(3−(2'-オキソスピロ[シクロプロパン−1,3'−インドリン]−1'-イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
MS for C33H37N5O4S
m/z 600 (M+H)+.
N−(4−(8−(3−(3,3−ジメチル−2−オキソインドリン−1−イル)プロピル)−4−オキソ−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)フェニル)メタンスルホンアミド
MS for C33H39N5O4S
m/z 602 (M+H)+.
2−((1−シクロヘキシル−4−オキソ−8−(4−オキソ−4−フェニルブチル)−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート, 塩酸塩
MS for C31H39N3O4
m/z 518 (M+H)+.
MS for C35H47N3O4
m/z 574 (M+H)+.
Claims (19)
- 式I
[式中、
R1は以下からなる群:
場合により3位がシクロプロピルで置換されている、または6位が塩素で置換されている(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)(C2−C4アルキル)、
(2−オキソベンゾ[d]オキサゾール−3(2H)−イル)(C2−C4アルキル)、
(2−オキソベンゾ[d]チアゾール−3(2H)−イル)(C2−C4アルキル)、
場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)(C2−C4アルキル)、
(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))(C2−C4アルキル)、
(2−オキソインドリン−3−イル))(C2−C4アルキル)、
フェニル(C1−C6アルキル)、
1−ヒドロキシ−1−フェニルメチル(C2−C6 アルキル)、
1−アセトキシオキシ−1−フェニルメチル(C2−C6 アルキル)、
ビス(4−フルオロフェニル)メチル−(C1−C6アルキル)、
(1H−ベンゾ[d][1,2,3]トリアゾール−1−イル)(C2−C4アルキル)、
場合によりフェニルの4位がハロで置換されている1−フェニル−1−オキソ−(C2−C6アルキル)、
2,3−ジヒドロベンゾ[b][1,4]ジオキサン−2−(C2−C4アルキル)、
1−(チオフェン−2−イル)−1−オキソ−(C1−C6アルキル)、
3−オキソ−2H−ベンゾ[b][1,4]オキサジン−4−イル−(C2−C4アルキル)、
(2−(シクロアルキル)−1H−ベンゾ[d]イミダゾール−1−イル)(C2−C4アルキル)、
((3−((C1−C6アルキル)カルボニルオキシ(メチル))−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
((3−(メトキシカルボニルエチル)−2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
((2−(t-ブトキシカルボニル)−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル))(C2−C4アルキル)、
1H−インダゾール−3−イル(C2−C4アルキル)、
(1−(インドリン−1−イル)−1−オキソ)(C2−C4アルキル)、
((3−(C1−C6アルキル)オキシカルボニル(C1−C6アルキル))−1H−インドール−1−イル)(C2−C4アルキル)、または
(2−(C1−C6アルキル)オキシカルボニル−1H−インドール−1−イル)(C2−C4アルキル)から選択され;
R2は、クロロ、フルオロまたはメトキシで場合によりパラ置換されているフェニル、直鎖または分岐鎖のC2−C6アルキル、場合により1〜6のハロゲンで置換されている3〜7炭素原子シクロアルキルであり;および
R3は、
R10はHまたは1〜6炭素のアルキルである]
で示される化合物またはその製薬的に許容し得る塩、またはその異性体。 - 式中R1が、場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)(C2−C4アルキル)、(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))(C2−C4アルキル)、(2−オキソインドリン−3−イル))(C2−C4アルキル)、または場合によりフェニルの4位がハロで置換されている1−フェニル−1−オキソ−(C2−C6アルキル)である、請求項1記載の化合物。
- 式中R3が式A, C, D、またはFで示され、R10がHである、請求項1記載の化合物。
- 式中R3が式 AまたはDで示される、請求項3記載の化合物。
- 式中R2がフェニルまたはシクロヘキシルである、請求項1記載の化合物。
- 式中R2がシクロヘキシルである、請求項5記載の化合物。
- 式中R2がフェニルである、請求項5記載の化合物。
- 式中R1が、場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)プロピル、(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))プロピル、(2−オキソインドリン−3−イル))プロピル、または場合によりフェニルの4位がハロで置換されている1−フェニル−1−オキソ−プロピルである、請求項1記載の化合物。
- R1が、場合により3位がメチルまたはフルオロから選択される1または2つで置換されている(2−オキソインドリン−1−イル)プロピル、(3−スピロシクロプロパン−(2−オキソインドリン−1−イル))プロピル、(2−オキソインドリン−3−イル))プロピル、または場合により4位がハロで置換されている1−フェニル−1−オキソ−プロピルであり;
R2が、フェニルまたはシクロヘキシルであり;および
R3が式 A, C, D、またはFで示され、R10がHである、請求項1記載の化合物。 - 式中R1が(2−オキソインドリン−1−イル)プロピルであり、R2がシクロヘキシルである、請求項9記載の化合物。
- 式中R3が式Aで示される、請求項10記載の化合物。
- 以下からなる群:
3−((4−オキソ−8−(3−(2−オキソ−2,3−ジヒドロ−1H−ベンゾ[d]イミダゾール−1−イル)プロピル)−1−フェニル−1,3,8−トリアザスピロ[4.5]デカン−3−イル)メチル)ベンゾエート
- 請求項1記載の化合物および少なくとも1つの製薬的に許容し得る添加剤を含有する組成物。
- D2またはD3アンタゴニスト活性に応答する状態を有するヒトの患者を処置するための方法であって、そのような処置を必要とする患者に請求項1記載の化合物を投与することを含んでなる方法。
- 胃腸運動促進剤が共に投与される請求項14記載の方法。
- 胃腸運動促進剤が、シサプリド、モサプリド、ベルセトラグまたはテガセロドである、請求項15記載の方法。
- 前記状態が、胃不全まひ、胃のうっ滞、過敏性腸症候群、機能性消化不良、胃食道逆流性疾患、胸焼け、便秘、術後イレウス、オピオイド誘発性イレウス、内臓過敏、食後窮迫症候群、術後の悪心嘔吐、化学療法誘発性の悪心嘔吐、周期性嘔吐症候群、胃炎、胃腸炎誘発性の悪心嘔吐、妊娠悪阻、片頭痛に関連する悪心、特発性の悪心嘔吐、慢性特発性悪心嘔吐、機能的な胆嚢障害、機能性Oddi胆管括約筋障害、機能性Oddi膵臓括約筋障害、下痢、胃律動不整、消化不良、上腹部膨満(上腹部膨満感)、早期満腹感、膨満、食後の膨満、腹痛、上腹部痛(症候群)、薬物依存、逆流ならびに消化管運動に対する高血糖性の阻害活性からなる群から選択される、請求項14記載の方法。
- 疼痛の処置方法であって、そのような処置を必要とする患者にオピオイド鎮痛薬とともに請求項1記載の化合物を投与することを含んでなる方法。
- オピオイド鎮痛薬が、モルヒネ、フェンタニル、トラマドール、スフェンタニル、アルフェンタニル、レミフェンタニル、カーフェンタニルおよびロフェンタニルからなる群から選択される、請求項18記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35609610P | 2010-06-18 | 2010-06-18 | |
US61/356,096 | 2010-06-18 | ||
PCT/US2011/040983 WO2011160084A1 (en) | 2010-06-18 | 2011-06-17 | D2 antagonists, methods of synthesis and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013528660A true JP2013528660A (ja) | 2013-07-11 |
JP2013528660A5 JP2013528660A5 (ja) | 2015-11-05 |
JP5860457B2 JP5860457B2 (ja) | 2016-02-16 |
Family
ID=44318118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013515569A Active JP5860457B2 (ja) | 2010-06-18 | 2011-06-17 | D2アンタゴニスト、その合成方法および使用方法 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8691836B2 (ja) |
EP (2) | EP3138841A1 (ja) |
JP (1) | JP5860457B2 (ja) |
KR (1) | KR101601383B1 (ja) |
CN (1) | CN103052636B (ja) |
AU (1) | AU2011268073B2 (ja) |
CA (1) | CA2802188C (ja) |
CY (1) | CY1118541T1 (ja) |
DK (1) | DK2582701T3 (ja) |
ES (1) | ES2612471T3 (ja) |
HR (1) | HRP20170134T1 (ja) |
HU (1) | HUE031556T2 (ja) |
IL (3) | IL223515A (ja) |
LT (1) | LT2582701T (ja) |
MX (2) | MX2012014470A (ja) |
NZ (1) | NZ605431A (ja) |
PL (1) | PL2582701T3 (ja) |
PT (1) | PT2582701T (ja) |
RS (1) | RS55645B1 (ja) |
SI (1) | SI2582701T1 (ja) |
SM (1) | SMT201700064B (ja) |
WO (1) | WO2011160084A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018519317A (ja) * | 2015-07-03 | 2018-07-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ddr1阻害剤としてのトリアザ−スピロデカノン |
JP2020519639A (ja) * | 2017-05-12 | 2020-07-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | トリアザスピロ[4.5]デカノンによる胃不全麻痺の処置 |
US12005042B2 (en) | 2017-02-10 | 2024-06-11 | Acacia Pharma Ltd. | Rescue treatment of post operative nausea and vomiting |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016204605B2 (en) * | 2009-06-25 | 2017-11-23 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
NZ605431A (en) | 2010-06-18 | 2015-06-26 | Altos Therapeutics Llc | D2 antagonists, methods of synthesis and methods of use |
AU2013370966A1 (en) | 2012-12-24 | 2015-06-18 | Neurogastrx, Inc. | Methods for treating GI tract disorders |
WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
EP3233077A4 (en) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamine d2 receptor ligands |
CN108884096B (zh) | 2016-02-08 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 作为ddr1抑制剂的螺二氢吲哚酮 |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002515503A (ja) * | 1998-05-18 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
BE633914A (ja) * | 1962-06-22 | |||
US3238216A (en) | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
US5182397A (en) | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
US6277991B1 (en) * | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
HUP0700269A2 (en) * | 2007-04-11 | 2009-04-28 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use |
PL2185155T3 (pl) * | 2007-08-03 | 2018-03-30 | Richter Gedeon Nyrt. | Kompozycje farmaceutyczne zawierające ligandy receptora dopaminy i sposoby leczenia z zastosowaniem ligandów receptora dopaminy |
NZ605431A (en) | 2010-06-18 | 2015-06-26 | Altos Therapeutics Llc | D2 antagonists, methods of synthesis and methods of use |
-
2011
- 2011-06-17 NZ NZ605431A patent/NZ605431A/en unknown
- 2011-06-17 AU AU2011268073A patent/AU2011268073B2/en active Active
- 2011-06-17 RS RS20170094A patent/RS55645B1/sr unknown
- 2011-06-17 ES ES11728491.9T patent/ES2612471T3/es active Active
- 2011-06-17 HU HUE11728491A patent/HUE031556T2/en unknown
- 2011-06-17 PL PL11728491T patent/PL2582701T3/pl unknown
- 2011-06-17 LT LTEP11728491.9T patent/LT2582701T/lt unknown
- 2011-06-17 US US13/163,592 patent/US8691836B2/en active Active
- 2011-06-17 CN CN201180037718.2A patent/CN103052636B/zh active Active
- 2011-06-17 JP JP2013515569A patent/JP5860457B2/ja active Active
- 2011-06-17 CA CA2802188A patent/CA2802188C/en active Active
- 2011-06-17 WO PCT/US2011/040983 patent/WO2011160084A1/en active Application Filing
- 2011-06-17 MX MX2012014470A patent/MX2012014470A/es active IP Right Grant
- 2011-06-17 DK DK11728491.9T patent/DK2582701T3/en active
- 2011-06-17 KR KR1020137000599A patent/KR101601383B1/ko active IP Right Grant
- 2011-06-17 PT PT117284919T patent/PT2582701T/pt unknown
- 2011-06-17 MX MX2014009737A patent/MX353209B/es unknown
- 2011-06-17 EP EP16192596.1A patent/EP3138841A1/en not_active Withdrawn
- 2011-06-17 SI SI201131089A patent/SI2582701T1/sl unknown
- 2011-06-17 EP EP11728491.9A patent/EP2582701B1/en active Active
-
2012
- 2012-12-09 IL IL223515A patent/IL223515A/en active IP Right Grant
-
2014
- 2014-02-19 US US14/184,615 patent/US9156840B2/en active Active
-
2017
- 2017-01-26 HR HRP20170134TT patent/HRP20170134T1/hr unknown
- 2017-01-27 SM SM201700064T patent/SMT201700064B/it unknown
- 2017-01-30 CY CY20171100133T patent/CY1118541T1/el unknown
- 2017-02-14 IL IL250606A patent/IL250606A0/en unknown
-
2018
- 2018-02-08 IL IL257429A patent/IL257429B/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002515503A (ja) * | 1998-05-18 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン |
Non-Patent Citations (4)
Title |
---|
JPN5013007548; MACH R H: 'EFFECT OF N-ALKYLATION ON THE AFFINITIES OF ANALOGUES OF SPIPERONE 以下備考' JOURNAL OF MEDICINAL CHEMISTRY V35 N3, 19920207, P423-430 * |
JPN5013007549; BAKTHAVACHALAM V: 'FLUORESCENT PROBES FOR DOPAMINE RECEPTORS: SYNTHESIS AND CHARACTERIZATION OF FLUORESCEIN 以下備考' EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY V34, 19910101, P3235-3241, EDITIONS SCIENTIFIQUE ELSEVIER * |
JPN6015021861; Thomsen, Christian; Hohlweg, Rolf: '(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl)acetic acid methyl ester (NNC' British Journal of Pharmacology 131(5), 2000, 903-908 * |
JPN6015021863; Metwally, Kamel A.; Dukat, Malgorzata; Egan, Christina T.; Smith, Carol; DuPre, Ann; Gauthier, Colle: 'Spiperone: Influence of Spiro Ring Substituents on 5-HT2A Serotonin Receptor Binding' Journal of Medicinal Chemistry 41(25), 1998, 5084-5093 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018519317A (ja) * | 2015-07-03 | 2018-07-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ddr1阻害剤としてのトリアザ−スピロデカノン |
JP7002335B2 (ja) | 2015-07-03 | 2022-01-20 | エフ.ホフマン-ラ ロシュ アーゲー | Ddr1阻害剤としてのトリアザ-スピロデカノン |
US12005042B2 (en) | 2017-02-10 | 2024-06-11 | Acacia Pharma Ltd. | Rescue treatment of post operative nausea and vomiting |
JP2020519639A (ja) * | 2017-05-12 | 2020-07-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | トリアザスピロ[4.5]デカノンによる胃不全麻痺の処置 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5860457B2 (ja) | D2アンタゴニスト、その合成方法および使用方法 | |
JP7193460B2 (ja) | Cdk8調節およびその適応症のための化合物および方法 | |
JP6353543B2 (ja) | 環縮小モルフィナン及びその使用 | |
JP5431341B2 (ja) | コルチコトロピン放出因子拮抗作用を有する三環系化合物及びそれらを含有する医薬組成物 | |
JP6212644B2 (ja) | フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性 | |
AU2014374043B2 (en) | TRPA1 modulators | |
US10435403B2 (en) | Positive allosteric modulators of muscarinic M2 receptor | |
TW201127838A (en) | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | |
WO2011021678A1 (ja) | 縮合複素環化合物 | |
EA033978B1 (ru) | Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств | |
JP6876625B2 (ja) | Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物 | |
CA3162767A1 (en) | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | |
ES2887674T3 (es) | 1-Arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
TW201321384A (zh) | 作為鈣通道阻斷劑之經取代之八氫吡咯并[1,2-a]吡□磺醯胺 | |
AU2009216149B2 (en) | Amide derivative and pharmaceutical composition containing the same | |
Luehr et al. | D 2 antagonists, methods of synthesis and methods of use | |
JP2011063586A (ja) | アミド誘導体からなる医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140610 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140610 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150609 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5860457 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |